



Vaccines and Global Health: The Week in Review
22 March 2025 :: Issue 791
Center for Vaccine Ethics & Policy (CVEP)

This weekly digest targets news, events, announcements, articles and research in the vaccine and global health ethics and policy space and is aggregated from key governmental, NGO, international organization and industry sources, key peer-reviewed journals, and other media channels. This summary proceeds from the broad base of themes and issues monitored by the Center for Vaccine Ethics & Policy in its work: it is not intended to be exhaustive in its coverage.

Vaccines and Global Health: The Week in Review is published as a PDF and scheduled for release each Saturday [U.S.] at midnight [0000 GMT-5]. The PDF is posted at <https://centerforvaccineethicsandpolicy.net>. This blog allows full text searching of over 27,000 entries.

Comments and suggestions should be directed to

David R. Curry, MS

Editor and

Executive Director Center for Vaccine Ethics & Policy

david.r.curry@centerforvaccineethicsandpolicy.org

Request email delivery of the pdf: *If you would like to receive the PDF of each edition via email [Constant Contact], please send your request to david.r.curry@centerforvaccineethicsandpolicy.org.*

Support this knowledge-sharing service: *Your financial support helps us cover our costs and to address a current shortfall in our annual operating budget. Click [here](#) to donate and thank you in advance for your contribution.*

Contents [click to move among sections]

:: [Milestones, Perspectives](#)

:: [WHO](#)

:: [Organization Announcements](#)

:: [Journal Watch](#)

:: [Pre-Print Servers](#)

:: [Think Tanks](#)

:: [Public Consultations/Call for Inputs/Call for Papers](#)

Milestones, Perspectives

.....
.....

Editor's Note:

Continuing our past practice, we present the full text of the "Highlights" report from the most recent WHO SAGE meeting below. We will also report on the full, official report to be published in the *Weekly Epidemiological Record* on 6 June 2025

WHO – Strategic Advisory Group of Experts (SAGE) on Immunization

Highlights from the Meeting of the Strategic Advisory Group of Experts (SAGE) on Immunization - 10-13 March 2025

(The full report will be published in the Weekly Epidemiological Record on 6 June 2025, and only the wording of the full report should be considered final)

Cross-cutting statements

- **During the last months, the world has witnessed a range of shifts that have profoundly impacted the health and development sectors.**
- **The current political and societal developments jeopardize global health, including vaccination programmes worldwide.**
- SAGE underlined the major contribution of vaccination to improved global child survival and health, while being one of the public health measures with the highest returns on investment.
- **SAGE expressed its deep concern about the current situation with the diversion of resources away from public health**, which creates a risk of further backsliding just when countries are recovering from the impact of the COVID-19 pandemic. This could adversely affect the ability of global immunization programmes to sustain the tremendous gains it has made and progress towards the goals of the Immunization Agenda 2030 (IA2030).

Session 1: Global & regional reports

Report from the Department of Immunization, Vaccines, and Biologicals.

- The report underscored the massive impact and progress made in global immunization to save lives and enhance health while acknowledging the unprecedented challenges ahead.
- As requested by SAGE, the report provided detailed insight into WHO's role in accelerating critical opportunities and overcoming key gaps that will enhance the impact of vaccination.
- Specific areas across the immunization value chain included WHO's role in the TB vaccine accelerator, strengthening vaccine regulatory capacity, regionalization of vaccine manufacturing, accelerating the rapid introduction and scale-up of malaria and HPV vaccines, innovations to break through the glass ceiling on immunization coverage, and reaching unvaccinated communities.
- However, **the report also highlighted the severe strain and threat to immunization programmes at global, regional and country levels with recent abrupt changes in donor budgets and capacity in global health and decreases in fiscal space domestically.**
- Most prominent are the threats to measles vaccine coverage improvements, disease surveillance, laboratory networks and outbreak response capacity, which are being acutely affected by budget cuts. WHO continues to provide leadership, coordination, country support and capacity strengthening as part of the Measles and Rubella Partnership, making all possible efforts to avert increases in preventable cases and deaths across countries that will result if the threats further materialize.
- Through strategic prioritization, innovation, and global collaboration, WHO supports countries in building resilient, equitable, and sustainable immunization programmes now and for the next 50 years and beyond, to harness safe, affordable and effective vaccines.

Update from Gavi, the Vaccine Alliance.

- The Gavi strategy 2026-2030 (Gavi 6.0) will be launched in 2026 with a focus on introducing and scaling up new vaccines, strengthening country programmes, supporting optimization and prioritization processes, ensuring sustainability, providing tailored support, and reducing zero-dose children.
- **The HPV initiative is on track to immunize 86 million girls by 2025, and significant progress has been made in rolling out malaria vaccines.**
- Gavi's new Health Systems Strategy focuses on equitable and sustainable immunization efforts through differentiated country support, consolidated funding, innovations, partnerships, and improved measurement.
- **Polio eradication remains a priority**, with Gavi investing US\$ 800 million in inactivated polio vaccines under the current strategy (Gavi 5.0), and the hexavalent vaccine* introductions planned for this year.
- **Gavi has allocated US\$ 5.6 million to address the mpox crisis and looks forward to establishing a vaccine stockpile** as part of Gavi 6.0 and document how the vaccine can contribute to broader disease control efforts.
- In 2024, Gavi approved 49 outbreak response requests and plans to support the use of diagnostics to strengthen data availability and decision-making.
 - * Containing diphtheria toxoid, tetanus toxoid, whole-cell pertussis, recombinant hepatitis B surface antigen, Haemophilus influenzae type b (Hib) conjugate and inactivated poliovirus vaccines.

Regional reports

- **Three regional reports highlighted the resurgence of measles and the need for urgent actions to mitigate the risk of large outbreaks** while noting the challenges with improving routine coverage and timely preventive vaccination activities. The problems could be further exacerbated with a shift in resources away from health, if current programme performance cannot be sustained, let alone further enhanced.
- **The number of zero-dose children has increased in some regions even after the restoration of routine immunization programmes following the COVID-19** pandemic response. While the Big Catch-up has helped, it has only partially addressed the problem and further efforts are required to fill immunity gaps.
- The report from the South-East Asian Region struck a positive note and reported on the successes with scaling up HPV vaccination; SAGE recommendations for the use of a single-dose schedule have made an important contribution to the scale-up.

Session 2: Immunization Agenda 2030 (IA2030): country-led monitoring

- Though many countries remain off track against key metrics for measuring progress against IA2030 indicators, there have been notable achievements such as the Big Catch-up and the scale-up of malaria and HPV vaccination.
- **The IA2030 Partnership Council has proposed three pivots in the IA2030 strategy: to increase advocacy, enhance a country-centred approach, and intensify inter-agency partnership and collaboration.**
- A review of 51 national immunization strategy (NIS) documents from low- and middle-income countries showed that countries are setting specific targets to reach IA2030 goals. Linkages to primary health care have been strengthened and NISs are increasingly being used to demonstrate country ownership and for resource mobilisation.
- The NIS is an opportunity to strengthen country data use for monitoring programme performance, implementing action cycles for programme improvement, and increasing accountability.
- Immunisation data systems in many countries lack the granularity, context, nuance or perspicacity to inform actions required to improve programme performance.

- Country-centred, continuous quality improvement processes supported by sufficiently capacitated WHO Regional and Country Offices, along with key partner engagement, are required to enable the required changes in programme monitoring.

Session 3: Pneumococcal vaccination of children

- **SAGE reaffirmed that achieving high coverage of three doses of pneumococcal conjugate vaccines (PCVs) using either a 3p+0† or a 2p+1‡ schedule is the most effective way to prevent childhood pneumococcal disease.** An update to the review of evidence from 2019, continued to show no conclusive advantage for either schedule over the other; the choice of schedules should be based on local epidemiological and programmatic factors.
 - † 3 primary doses without a booster dose
 - ‡ 2 primary doses with 1 booster dose
 - § 1 primary dose with 1 booster dose
- In addition to two currently WHO-prequalified vaccines, PCV10 (Synflorix®, GlaxoSmithKline) and PCV13 (Prevenar13®, Pfizer), recent evidence supports the use of a third WHO-prequalified PCV10 (Pneumosil®, Serum Institute of India) for routine immunization of infants using either of the two recommended 3-dose schedules.
- Countries considering switching to recently licensed higher valency PCV product (e.g., PCV14, PCV15, PCV20) to broaden serotype coverage must consider trade-offs that may exist, particularly the potential reduced direct and indirect protection against serotypes in common with PCV10 / PCV13, noting that antibody concentrations tend to be reduced as the number of serotypes in the product increases.
- **Countries with mature PCV programmes that have achieved adequate levels of herd immunity can consider one of two cost-saving strategies:** (i) the use of a reduced dose 1p+1 schedule§; or (ii) the use of a 40% fractional dose of PCV13 (the only product for which evidence supported fractional dose use). Both strategies require high vaccination coverage, and careful impact and coverage monitoring with contingency plans to revert to full 3-dose schedules if indicated.
- **In settings with evidence of or suspected insufficient population immunity (e.g., high disease burden, persistently low vaccination coverage, and humanitarian emergencies), multi-age cohort (MAC) campaigns with a single dose of PCV should be considered;** MAC campaigns should not replace or divert resources from routine programmes for immunization with PCVs.
- Establishing capacity for pneumococcal surveillance (disease and/or carriage) in early-adopter countries, ideally a few representative surveillance sites in each WHO region, is desirable to generate real-world evidence of the effectiveness of new pneumococcal vaccines and alternative dosing strategies.

Session 4: Mpox

- A second mpox public health emergency of international concern (PHEIC) was declared in August 2024 related to the emergence of a new virus clade (Ib), and its spread across African countries. While mpox continues to be reported in all WHO Regions, the number of cases is increasing in Africa.
- **Five African countries have initiated vaccination** and over 582 000 vaccine doses have been administered in the Democratic Republic of the Congo alone as of 16 March 2025. However, with the acceleration of vaccination activities, vaccine supply is again constrained.
- Current WHO recommendations allow for the “off-label” use of a single dose or an intradermal fractional dose of MVA-BN in supply-constrained outbreak situations; SAGE recommended consideration of these strategies if indicated.
- SAGE noted that while pre- and post-exposure vaccination to control the ongoing outbreak was appropriate under the current circumstances, the next phase should focus on preventive e

vaccination. However, evidence gaps remain to inform strategies for preventive vaccination implementation, and research is ongoing to fill these gaps.

- **SAGE expressed concern about reduced funding for HIV/AIDS control programmes, which could lead to a resurgence of HIV infections** and a rise in the number of people living with undiagnosed or uncontrolled HIV, who are particularly vulnerable to severe mpox.

Session 5: Varicella & Herpes Zoster

- Varicella and herpes zoster cause significant morbidity worldwide. The cost-effectiveness of vaccination based on current vaccine prices would vary between countries and would only be considered cost-effective in most countries based on overall economic benefits, including productivity loss of caregivers.
- **SAGE recommended that the use of varicella vaccines using a 2-dose schedule with a minimum 4-week interval between doses be considered for the prevention of varicella in children in populations where varicella is an important public health problem.**
- Countries introducing the varicella vaccine should define vaccination coverage targets, guided by criteria including national and subnational disease burden, affordability, cost-effectiveness, seroprevalence rates and age of infection acquisition to avoid the theoretical risk of a shift in the age of infection resulting in higher morbidity if coverage is low or modest.
- SAGE also recommended consideration of varicella vaccination of special populations, including certain groups who are at risk for severe disease. Vaccination may be offered to immunocompromised and those living with well-controlled HIV infection and adequate CD4 counts.
- Further, vaccination is recommended for health care workers without documented evidence of prior VZV infection or vaccination. The aim is to avoid onward transmission to susceptible patient groups, particularly when caring for immunocompromised persons, as well as for personal protection, particularly if caring for children.
- SAGE recommended that the use of the recombinant herpes zoster vaccine in a 2-dose schedule with a minimum 2-month interval between doses, for the prevention of herpes zoster in older adults, those with chronic conditions and the immunocompromised, be considered in countries where herpes zoster is an important public health problem. SAGE advised countries to conduct cost-effectiveness analyses to inform decision-making.

Session 6: Global progress in National Immunization Technical Advisory Group (NITAG) strengthening

- There has been remarkable progress with the establishment and functionality of NITAGs globally. However, **NITAGs in many middle-income countries face challenges that impede optimal functionality, including inadequate secretariat support.**
- SAGE noted the increasing importance of NITAGs in advising governments on vaccine introduction prioritization, vaccine portfolios and immunization schedules optimization, as well as their role in programme monitoring.
- SAGE encouraged efforts to sustain and further enhance the capacity of NITAGs, advocated for periodic evaluations of their capacity and functioning, and reiterated the need for sub-regional immunization technical advisory groups to serve countries with small populations and inadequate breadth of technical capacity.
- SAGE called for countries to demonstrate their commitment to NITAGs by increasing domestic funding to support the NITAG secretariats and their operations, including through enacting legislation that recognizes the role, importance and functionality of NITAGs.
- **SAGE applauded the strong coordination of NITAG support through the Global NITAG Network** and called on WHO and partners to continue supporting this initiative.

Session 7: Prioritization of new vaccine introduction

- **In the context of an increasing number of available vaccines, SAGE emphasized that each country should be empowered to prioritize these vaccines and determine the**

timing of the introduction of the vaccines into national programmes. These decisions should be made using a systematic, country-owned process based on the local context.

- SAGE acknowledged that NITAGs play a crucial role in leading a deliberate evidence-based approach leveraging available tools such as multi-criteria decision analysis (MCDA) and engaging relevant stakeholders.
- SAGE called on countries to engage their NITAG in providing recommendations on the prioritization of new vaccines for introductions and optimization of vaccination schedules and portfolios in close consultation with their respective national immunization programmes. These recommendations need to be aligned and integrated with the priorities in their NIS and health sector strategy and regularly updated.
- **SAGE noted the challenges countries face with access to evidence to support informed choices and called on WHO and all partners to strengthen coordination in this area.**

Session 8: Poliomyelitis

- **SAGE was highly concerned about the continued transmission of wild poliovirus in Pakistan and Afghanistan and the overall lack of efforts towards a transformative change in strategy to complete poliovirus eradication.**
- **SAGE expressed concern about the continued circulation of vaccine-derived poliovirus type 2 and its expansion into new areas**, including European countries as demonstrated by environmental surveillance, and stressed the urgent and compelling need for increased improvements in routine immunization coverage and to reach zero-dose children with catch-up doses.
- **SAGE reiterated its support for the safe eventual global cessation of bOPV** and agreed with plans for pre-cessation bOPV vaccination campaigns based on the proposed methods to determine the need for such campaigns.
- SAGE endorsed the proposed risk-grading framework as a guide for discussions with countries considering transitioning to IPV-only routine immunization schedules in advance of a global bOPV withdrawal and urged WHO to initiate consultations on this topic with its Member States and Regional Offices.
- **SAGE reviewed updated evidence and concluded that a polio vaccination schedule with a minimum of three doses of the IPV** (-containing) vaccine, such as the IPV-containing whole-cell pertussis hexavalent vaccine, starting at 6 weeks of age or later is adequate, without the need for a scheduled IPV booster dose (4th dose) and revised existing recommendations accordingly. However, SAGE emphasized that if schedules do not programme a 4th dose as a booster (which may serve as a possibility to catch-up children that have missed previous doses), it is essential that children receive all 3 doses. This recommendation does not change WHO's existing recommendations for providing booster doses of other antigens in the second year of life, namely diphtheria-tetanus-pertussis containing vaccines.

.....
.....

TB

WHO calls for urgent action to address worldwide disruptions in tuberculosis services putting millions of lives at risk

20 March 2025 *News release*

On the occasion of World Tuberculosis (TB) Day, marked on 24 March, the World Health Organization (WHO) is calling for an urgent investment of resources to protect and maintain tuberculosis (TB) care and support services for people in need across regions and countries. TB remains the world's deadliest infectious disease, responsible for over 1 million people annually bringing devastating impacts on families and communities...

Under the theme *Yes! We Can End TB: Commit, Invest, Deliver*, [World Tuberculosis Day 2025](#) campaign highlights a rallying cry for urgency, and accountability and hope.

“The huge gains the world has made against TB over the past 20 years are now at risk as cuts to funding start to disrupt access to services for prevention, screening, and treatment for people with TB,” said Dr Tedros Adhanom Ghebreyesus, WHO Director-General. “But we cannot give up on the concrete commitments that world leaders made at the UN General Assembly just 18 months ago to accelerate work to end TB. WHO is committed to working with all donors, partners and affected countries to mitigate the impact of funding cuts and find innovative solutions.”

Funding: threat to global TB efforts

Early reports to WHO reveal that severe disruptions in the TB response are seen across several of the highest-burden countries following the funding cuts. Countries in the WHO African Region are experiencing the greatest impact, followed by countries in the WHO South-East Asian and Western Pacific Regions.

Twenty seven countries are facing crippling breakdowns in their TB response, with devastating consequences, such as:

- :: Human resource shortages undermining service delivery;
- :: Diagnostic services severely disrupted, delaying detection and treatment;
- :: Data and surveillance systems collapsing, compromising disease tracking and management;
- :: Community engagement efforts, including active case finding, screening, and contact tracing, deteriorating, leading to delayed diagnoses and increased transmission risks.

Nine countries report failing TB drug procurement and supply chains, jeopardizing treatment continuity and patient outcomes.

The 2025 funding cuts further exacerbate an already existing underfunding for global TB response. In 2023, only 26% of the US\$22 billion annually needed for TB prevention and care was available, leaving a massive shortfall. TB research is in crisis, receiving just one-fifth of the US\$5 billion annual target in 2022—severely delaying advancements in diagnostics, treatments, and vaccines. WHO is leading efforts to accelerate TB vaccine development through the TB Vaccine Accelerator Council, but progress remains at risk without urgent financial commitments.

Joint statement with civil society

In response to the urgent challenges threatening TB services worldwide, WHO’s Director-General and Civil Society Task Force on Tuberculosis have issued a decisive statement. **The [joint statement](#) released this week, demands immediate, coordinated efforts from governments, global health leaders, donors, and policymakers to prevent further disruptions.**

The statement outlines five critical priorities:

- :: *Addressing TB service disruptions* urgently, ensuring responses match the crisis's scale;
- :: *Securing sustainable domestic funding*, guaranteeing uninterrupted and equitable access to TB prevention and care;
- :: *Safeguarding essential TB services*, including access to life-saving drugs, diagnostics, treatment and social protections, alongside cross-sector collaboration;
- :: *Establishing or revitalizing national collaboration platforms*, fostering alliances among civil society, NGOs, donors, and professional societies to tackle challenges;
- :: *Enhancing monitoring and early warning systems* to assess real-time impact and detect disruptions early...

On World TB Day, WHO calls on everyone: individuals, communities, societies, donors and governments, to do their part to end TB. Without concerted action from all stakeholders, the TB response will be decimated, reversing decades of progress, putting millions of lives at risk and threatening health security.

.....
.....

Cholera

Multi-country cholera outbreak, external situation report #24 -20 March 2025

WHO – 20 March 2025

External Situation Report n. 24, published 20 March 2025

Cases – 70 488
Since Jan. 2025

Deaths – 808
Since Jan. 2025

Countries affected – 23
Since Jan. 2025

Population at risk
1 billion

Global risk –
Very high

Overview

Data as of 23 February 2025

- **In February 2025 (epidemiological weeks 5 to 8), a total of 32 613 new cholera and / or acute watery diarrhoea (AWD) cases were reported from 21 countries**, territories, areas (hereafter countries) across three WHO regions, reflecting a 14% decrease from January 2025. The African Region registered the highest number of cases, followed by the Eastern Mediterranean Region and the South-East Asia Region. **The period also saw 459 cholera-related deaths globally**, highlighting a 32% increase from the previous month.
- While the seasonal decline in transmission during winter months may partly explain the reduction in case numbers in some regions, the overall cholera data remains incomplete due to underreporting and reporting delays.
- Additionally, extreme weather events and conflict, such as the ongoing insecurity in the Democratic Republic of the Congo, have resulted in low or no reporting from some areas. **Given these complexities, the data presented here likely underestimates the true burden of cholera and should be interpreted with caution.**
- Since January 2025, 23 countries have reported cholera / AWD outbreaks, most of which are continuations from the previous year.
- **Conflict, mass displacement, disasters from natural hazards, and climate change have intensified outbreaks**, particularly in rural and flood-affected areas, where poor infrastructure and limited healthcare access delay treatment. These cross-border factors have made cholera outbreaks increasingly complex and harder to control.
- From 1 January to 23 February 2025, a cumulative total of 70 488 cholera cases and 808 deaths were reported from 23 countries across three WHO regions, with the African Region recording the highest numbers, followed by the Eastern Mediterranean Region and the South-East Asia Region.
- **In February, Oral Cholera Vaccine (OCV) production remained at a high level, reflecting significant efforts by the supplier and partners:** The introduction and prequalification of an improved vaccine formulation and manufacturing process earlier in 2024 **allowed the average stockpile to stabilize at 5.5 million doses in February, the third consecutive month above the five million needed for emergency stockpile at all times.**
- **However, growing global demand continues to exceed supply, hindering efforts to control cholera outbreaks, respond rapidly to the disease's spread, and implement preventative campaigns**

Operational updates

...Vaccination

- OCV production remained robust in February 2025, reflecting significant efforts by the supplier and partners following the introduction and prequalification of a new vaccine formulation and manufacturing process in 2024.
- The global OCV stockpile averaged 5.5 million doses in February, with only one week below the target of five million doses that should be available at all times for outbreak response.
- **Seventeen new emergency requests were submitted in the two first months of 2025 – compared to three in 2024** by Angola (2), DR Congo (2), Ethiopia, Ghana (3), Myanmar, Nigeria, South Sudan (5), Sudan (2) collectively seeking 17 million doses for single round campaigns (compared to eight million in 2024). Sixteen requests were approved, while one was not approved by the International Coordinating Group (ICG) on Vaccine Provision.
- Since the start of 2025, **ten countries (Angola, Bangladesh, Ghana, Malawi, Mozambique, Myanmar, Niger, South Sudan, Sudan and Zambia) have conducted 17 reactive vaccination campaigns**, targeting a total of eight million people. Due to limited vaccine availability, only single-dose vaccination campaigns have been approved and implemented.
- Despite these efforts, the **growing demand for OCV continues to exceed supply, severely constraining preventive vaccination campaigns**. Urgent expansion of vaccine production remains critical.

.....
.....

mPox – PHEIC

Third meeting of the International Health Regulations (2005) Emergency Committee regarding the upsurge of mpox 2024

17 March 2025 *Statement*

The Director-General of the World Health Organization (WHO) is hereby transmitting the report of the third meeting of the International Health Regulations (2005) (IHR) Emergency Committee (Committee) regarding the upsurge of mpox 2024, held on Tuesday, 25 February 2025, from 12:00 to 17:00 CET.

Concurring with the advice unanimously expressed by the Committee during the meeting, the WHO Director-General determined that the upsurge of mpox 2024 continues to meet the criteria of a public health emergency of international concern (PHEIC) and, accordingly, on 27 February 2025, issued temporary recommendations to States Parties...

Conclusions

The Committee reiterated its concern regarding the continuing spread of MPXV in and beyond Africa, considering global geopolitical developments, the humanitarian situation in the DRC, as well as the foreseeable options and opportunities to secure sustainable funding to support response efforts. The Committee considered that the determination by the WHO Director-General that the upsurge of mpox still constitutes a PHEIC would be warranted.

However, the Committee cautioned about the possible unintended consequences of determining an event to constitute a PHEIC for extended periods of time, since this could undermine the global public health alert function intrinsic to such a determination and reduce the leverage of a PHEIC in boosting domestic and international response efforts for future events. To that effect, the Committee reiterated the need to elaborate on considerations, related to the three criteria defining a PHEIC, that would inform its future advice to the WHO Director-General as to the termination of this PHEIC.

.....
.....

Polio – PHEIC

Polio this week – 12 March 2025

Headlines

:: The summary report following last week's meeting of the Strategic Advisory Group of Experts on immunization (SAGE) is available [here](#).

:: Gaza outbreak response video – please click [here](#) to view a short video on last month's polio outbreak response campaign implemented in Gaza. The campaign reached more than 600,000 children under the age of ten years.

Summary of new polioviruses this week, cases and positive environmental isolates:

- Pakistan: 12 WPV1-positive environmental samples
- Angola: one cVDPV2 case and one cVDPV2-positive environmental sample
- Chad: one cVDPV2-positive environmental sample
- Côte d'Ivoire: one cVDPV2-positive environmental sample
- Djibouti: three cVDPV2-positive environmental samples
- Ethiopia: one cVDPV2-positive environmental sample
- Nigeria: one cVDPV2 case
- Somalia: four cVDPV2 cases and one cVDPV2-positive environmental sample
- Yemen: five cVDPV2-positive environmental samples

.....
.....

Contents [click to move among sections]

:: [Milestones, Perspectives](#)

:: [WHO](#)

:: [Organization Announcements](#)

:: [Journal Watch](#)

:: [Pre-Print Servers](#)

.....
.....

WHO & Regional Offices [to 22 Mar 2025]

<https://www.who.int/news>

Selected News/Announcements/Statements

20 March 2025 *News release*

WHO calls for urgent action to address worldwide disruptions in tuberculosis services putting millions of lives at risk

17 March 2025 *Statement*

Third meeting of the International Health Regulations (2005) Emergency Committee regarding the upsurge of mpox 2024

17 March 2025 *News release*

Nearly 50 million people sign up call for clean air action for better health

.....

WHO Regional Offices

Selected Press Releases, Announcements

WHO African Region AFRO

:: 02 April 2025

[Election of new WHO Regional Director for Africa: candidates' forum](#)

:: 21 March 2025

[African region records further decline in TB deaths, cases](#)

WHO Region of the Americas PAHO

:: 18 Mar 2025

[PAHO ultra-portable telehealth kit brings specialist primary healthcare services to remote communities in the Americas](#)

Washington D.C. 18 March 2025 (PAHO) – The management of complex cardiovascular disease, specialist prenatal ultrasounds, and the diagnosis of communicable diseases such as tuberculosis can now be carried out even in the most remote parts of the Americas thanks to the launch of the Pan American Health Organization's (PAHO) telehealth kits. The...

WHO South-East Asia Region SEARO

No new digest content identified.

WHO European Region EURO

No new digest content identified.

WHO Eastern Mediterranean Region EMRO

:: 17 March 2025

[Eighty percent of WHO-supported facilities in Afghanistan risk shutdown by June](#)

WHO Western Pacific Region

No new digest content identified.

.....

WHO - Emergency situation reports

Latest WHO official reports for emergency situations. Latest WHO official reports for emergency situations.

[Sudan conflict and refugee crisis, Multi-country External Situation Report #9, covering the reporting period January-February 2025](#)

[Multi-country cholera outbreak, external situation report #24 -20 March 2025](#)

.....

Disease Outbreak News (DONs)

Latest WHO Disease Outbreak News (DONs), providing information on confirmed acute public health events or potential events of concern.

No new digest content identified.

.....

Weekly Epidemiological Record

Vol. 100, No. 12, pp. 91–102 21 March 2025

<https://www.who.int/publications/journals/weekly-epidemiological-record>

PDF: <https://iris.who.int/bitstream/handle/10665/380850/WER10012-eng-fre.pdf>
:: Recommended composition of influenza virus vaccines for use in the 2025–2026 northern hemisphere influenza season

.....

New WHO Publications

<https://www.who.int/publications>

Selected

21 March 2025

[Country experiences on implementation of traceability for medical products](#)

21 March 2025

[Compendium of best practices and case studies in quality of care, patient safety, infection prevention...](#)

20 March 2025

[Asia-Pacific Rabies Meeting Bangkok, Thailand, 16–18 July 2024](#)

20 March 2025

[Meeting of Regional Partners' Forum: Sustain, accelerate and innovate to end neglected tropical diseases...](#)

20 March 2025

[Integrated approach to tuberculosis and lung health](#)

19 March 2025

[Infection prevention and control and water, sanitation and hygiene in health facilities during Ebola...](#)

19 March 2025

[Regional Workshop on conversion of emergency use authorization to full marketing authorization for pandemic...](#)

.....

.....

USA – HHS, FDA, CDC+

Editor's Note:

We employ bolded red text below to identify observations we assess might be useful to readers.

HHS

News

No new digest content identified.

FDA

Press Announcements

No new digest content identified.

FDA VRBPAC

Advisory Committee Calendar

The Advisory Committee calendar does not list any future scheduled meetings of any FDA advisory committee, including VRBPAC.

CDC/ACIP [U.S.] [to 22 Mar 2025]

<http://www.cdc.gov/media/index.html>

Latest News

No new digest content identified.

ACIP Meetings [to 22 Mar 2025]

Next ACIP Meeting

ACIP Meeting February 26-28, 2025 Postponed

"The ACIP meeting will be postponed to accommodate public comment in advance of the meeting. The ACIP workgroups met as scheduled this month and will present at the upcoming ACIP meeting."

Agenda for February 26-28

[Agenda appears stable from earlier agenda versions]

National Vaccine Program

<https://www.hhs.gov/vaccines/about/index.html>

Upcoming Meetings/Latest Updates

No 2025 meeting dates posted.

MMWR Weekly

<https://www.cdc.gov/mmwr/index2025.html>

March 20, 2025 / No. 9

[PDF of this issue](#)

- Case Finding Among and Comprehensive Management of Household Contacts of Persons with Pulmonary Tuberculosis: a Pilot Project — Uganda, 2023–2024

.....
.....

Europe

European Medicines Agency [EMA]

<https://www.ema.europa.eu/en/news>

News & Press Releases

Joint strategy sets direction of EMA and EU medicines regulatory agencies to 2028

Seizing opportunities in a changing medicines landscape

18 March 2025

EMA and the Heads of Medicines Agencies (HMA) have published their joint EU medicines agencies' network strategy to 2028 (EMANS), following its recent adoption by the HMA and the EMA Management Board.

The strategy, titled 'Seizing opportunities in a changing medicines landscape', is a comprehensive update of the five-year strategy which was developed to cover the period 2021 to 2025 (EMANS 2025). The updated document will guide the European medicines regulatory network over the next few years to meet the challenges ahead, including preparing for, and responding to, public health emergencies and threats such as antimicrobial resistance.

European Centre for Disease Prevention and Control

<https://www.ecdc.europa.eu/en>

News/Updates/Reports/Publications [Selected]

News

ECDC and Africa CDC discuss deeper collaboration for global health security

18 Mar 2025

Surveillance and monitoring

Influenza virus characterization - Summary Europe, November 2024

21 Mar 2025

This report contains genetic and antigenic characterization data generated at the Worldwide Influenza Centre for viruses with collection dates after 1 February 2024 until 31 August 2024.

Surveillance and monitoring

Avian influenza overview December 2024-March 2025

21 Mar 2025

Between 7 December 2024 and 7 March 2025, 743 highly pathogenic avian influenza (HPAI) A(H5) virus detections were reported in domestic (239) and wild (504) birds across 31 countries in Europe.

.....

.....

Africa CDC [to 22 Mar 2025]

<https://africacdc.org/>

Press Releases, Statements [Selected]

Africa CDC Launches New Podcast to Drive Health Impact Across the Continent

21 March 2025

Press Releases

ECDC and Africa CDC discuss deeper collaboration for global health security

19 March 2025

.....

China CDC+

<http://www.chinacdc.cn/en/>

National Health Commission of the People's Republic of China [to 22 Mar 2025]

<http://en.nhc.gov.cn/>

News

No new digest content identified.

National Medical Products Administration – PRC [to 22 Mar 2025]

<http://english.nmpa.gov.cn/>

News

Measures facilitate approval of 48 first-in-class innovative drugs

2025-03-21

China approved 48 first-in-class innovative drugs, as well as a significant number of medications for pediatric and rare diseases, thanks to measures aimed at enhancing review efficiency and accelerating patient access to novel therapies, according to a report released on Tuesday by the National Medical Products Administration.

China CDC

CCDC Weekly Reports: Current Volume (7)

2025-03-21 / No. 12

[PDF of this issue](#)

- [Perspectives: Climate Change, Cryosphere Retreat, and Human Health](#)
- [Policy Notes: Policy Interpretation of the China National Climate Change Health Adaptation Action Plan \(2024–2030\)](#)
- [Preplanned Studies: Human Infection with Chlamydia pneumoniae ST16 — Lishui City, Zhejiang Province, China, 2024](#)
- [Outbreak Reports: The First Imported Case of Lassa Fever — China, 2024](#)

.....

Contents [click to move among sections]

:: [Milestones, Perspectives](#)
 :: [WHO](#)
 :: [Organization Announcements](#)
 :: [Journal Watch](#)
 :: [Pre-Print Servers](#)

.....

Organization Announcements

Paul G. Allen Frontiers Group [to 22 Mar 2025]

<https://alleninstitute.org/news-press/>

News

[Breakthrough Dravet Syndrome gene therapy in mice brings new hope to families](#)

Mar 19, 2025

In a groundbreaking advancement scientists have developed a new gene replacement therapy in mice that could lead to more effective treatments in...

BMGF - Gates Foundation [to 22 Mar 2025]

<https://www.gatesfoundation.org/ideas/media-center>

Press Releases & Statements

No new digest content identified.

Bill & Melinda Gates Medical Research Institute [to 22 Mar 2025]

<https://www.gatesmri.org/news>

The Bill & Melinda Gates Medical Research Institute is a non-profit biotech organization. Our mission is to develop products to fight malaria, tuberculosis, and diarrheal diseases—three major causes of mortality, poverty, and inequality in developing countries. The world has unprecedented scientific tools at its disposal; now is the time to use them to save the lives of the world's poorest people

News: Articles and Publications

No new digest content identified.

CARB-X [to 22 Mar 2025]

<https://carb-x.org/>

News

No new digest content identified.

Chan Zuckerberg Initiative [to 22 Mar 2025]

<https://chanzuckerberg.com/newsroom/>

Newsroom

No new digest content identified.

CEPI – Coalition for Epidemic Preparedness Innovations [to 22 Mar 2025]

<http://cepi.net/>

CEPI News, Blog

News

[CEPI and AstraZeneca to advance discovery into novel antibody to help prevent infection during outbreaks](#)

19 Mar 2025

:: Collaboration to establish proof-of-concept for innovative antibody that could reduce costs and increase global access to antibody-based interventions compared to existing monoclonal antibodies.

:: Novel antibody technology could help tackle future infectious disease outbreaks and pandemics swiftly and more affordably.

News

[Exploiting fungus growth for rapid and affordable vaccine development](#)

18 Mar 2025

CEPI is providing US\$4.5 million to non-profit Fondazione Biotechnopolo di Siena (FBS) for proof-of-concept research that will explore whether producing antigens in C1 filamentous fungus—applying technology owned by Dyadic International (Nasdaq:DYAI)—is a faster and cost-effective alternative to the more established route of producing antigens in mammalian cells.

CIOMS – COUNCIL FOR INTERNATIONAL ORGANIZATIONS OF MEDICAL SCIENCES [to 22 Mar 2025]

<https://cioms.ch/>

News; Publications; Events

No new digest content identified.

DARPA – Defense Advanced Research Projects Agency [U.S.] [to 22 Mar 2025]

<https://www.darpa.mil/news>

News

No new digest content identified.

DNDI – Drugs for Neglected Diseases initiative [to 22 Mar 2025]

<https://dndi.org/press/press-releases/>

Press Releases

18 Mar 2025

[DNDi welcomes GHIT support for new collaboration with Shionogi to identify novel drug candidates for neglected Chagas disease](#)

Duke Global Health Innovation Center [to 22 Mar 2025]

<https://dukeghic.org/>

News

Issue 10: 20 March 2025 | Mpox: Transparency and Accountability for the Global Response

March 20, 2025

Welcome to the tenth issue of our report, "Mpox: Transparency and Accountability for the Global Response." In the wake of the U.S. health agencies' communications and foreign aid freezes, w...

EDCTP [to 22 Mar 2025]

<http://www.edctp.org/>

The European & Developing Countries Clinical Trials Partnership (EDCTP) aims to accelerate the development of new or improved drugs, vaccines, microbicides and diagnostics against HIV/AIDS, tuberculosis and malaria as well as other poverty-related and neglected infectious diseases in sub-Saharan Africa, with a focus on phase II and III clinical trials

No new digest content identified.

Emory Vaccine Center [to 22 Mar 2025]

<http://www.vaccines.emory.edu/>

Vaccine Center News

No new digest content identified.

European Vaccine Initiative [to 22 Mar 2025]

<http://www.euvaccine.eu/>

Latest News, Events

No new digest content identified.

Fondation Merieux [to 22 Mar 2025]

<http://www.fondation-merieux.org/>

News, Events

No new digest content identified.

Gavi [to 22 Mar 2025]

<https://www.gavi.org/>

Press Releases

17 March 2025

Burundi introduces malaria vaccine into routine immunization

GE2P2 Global Foundation [to 22 Mar 2025]

www.ge2p2.org

News/Analysis/Publications-Digests/Statements

:: [Vaccines and Global Health: The Week in Review](#) - Current edition

:: [Informed Consent: A Monthly Review – March 2025](#)

:: [Public Consultations Watch :: Global Calls for Input/Public Comment – 20 Mar 2025](#)

:: [Genomics :: Governance, Ethics, Policy, Practice – A Monthly Digest – March 2025](#)

GHIT Fund [to 22 Mar 2025]

<https://www.ghitfund.org/newsroom/press>

Press Releases

March 18, 2025

Total Investment of Approx. USD 11.4 Million in Schistosomiasis Diagnostics and R&D projects for NTDs with Partners including Drugs & Diagnostics for Tropical Diseases and Medical & Biological Laboratories

Global Fund [to 22 Mar 2025]

<https://www.theglobalfund.org/en/news/>

News Releases

No new digest content identified.

Global Research Collaboration for Infectious Disease Preparedness [GloPID-R] [to 22 Mar 2025]

<https://www.glopid-r.org/news/>

News

No new digest content identified.

Hilleman Laboratories [to 22 Mar 2025]

<http://www.hilleman-labs.org/>

News & Insights

No new digest content identified.

HHMI - Howard Hughes Medical Institute [to 22 Mar 2025]

<https://www.hhmi.org/news>

Press Room

No new digest content identified.

Human Immunome Project [nee Human Vaccines Project] [to 22 Mar 2025]

<https://www.humanimmunomeproject.org/>

News

No new digest content identified.

IAVI [to 22 Mar 2025]

<https://www.iavi.org/>

Press Releases, Features

In The News

Lassa Fever Vaccine Clinical Trial Begins, Marking Key Step Forward

March 17, 2025

INSERM [to 22 Mar 2025]

<https://www.inserm.fr/en/home/>

Press Releases

No new digest content identified.

International Coalition of Medicines Regulatory Authorities [ICMRA]

<http://www.icmra.info/drupal/en/news>
Selected Statements, Press Releases, Research
19 March 2025

[Extension of the ICMRA PQKM Collaborative Pilots](#)

ICH [International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use] [to 22 Mar 2025]

<https://www.ich.org/>
News/Pubs/Press Releases [Selective]
22 March 2025

[ICH M13B Draft Guideline & Step 2 Presentation Now Available on the ICH Website](#)

The ICH M13B draft Guideline on Bioequivalence for Immediate-Release Solid Oral Dosage Forms – Additional Strengths Biowaiver reached Step 2b of the ICH Process on 13 March 2025 and entered the public consultation period.

22 March 2025

[ICH M11 Updated Technical Specification Document Now Available on the ICH Website](#)

The ICH M11 updated version of the Technical Specification document, which incorporates comments received during the first public consultation, reached Step 2b of the ICH process in March 2025 and now enters the second round of public consultation. [M11 EWG Clinical electronic Structured Harmonised Protocol (CeSHarP)]

ICRC [to 22 Mar 2025]
<https://www.icrc.org/en/whats-new>
Latest press releases and statements [Selected]
News release 10-03-2025

[ICRC Regional Director, Nicolas Von Arx, warns of catastrophic consequences for civilians caught up in endless escalations in the Middle East](#)

News release 21-03-2025

[ICRC brings together experts to explore how upholding rules of war can help facilitate peace](#)

News release 20-03-2025

[Israel and the occupied territories: Red Cross Field Hospital responding to increased number of casualties in Gaza](#)

News release 19-03-2025

[Advancing Protection of Health Care: Expert Meeting on the Regulation and Perception of Distinctive Emblems and Other Signs and Symbols Used to Identify Health-care Facilities, Vehicles and Personnel](#)

Publication 10-03-2025

IFFIm

<http://www.iffim.org/>
Press Releases/Announcements
No new digest content identified.

IFRC [to 22 Mar 2025]

<http://media.ifrc.org/ifrc/news/press-releases/>

Press Releases [Selected]

[Statement: Medical services overwhelmed as airstrikes hit Gaza](#)

18/03/2025 | *Press release*

IPPS - International Pandemic Preparedness Secretariat [to 22 Mar 2025]

<https://ippsecretariat.org/news/>

News

No new digest content identified.

Institut Pasteur [to 22 Mar 2025]

<https://www.pasteur.fr/en/press-area>

Press Documents

No new digest content identified.

ISC / International Science Council [to 22 Mar 2025]

<https://council.science/current/>

ISC is a non-governmental organization with a unique global membership that brings together 40 international scientific Unions and Associations and over 140 national and regional scientific organizations including Academies and Research Councils.

Latest Updates

No new digest content identified.

International Union of Immunological Societies (IUIS)

<https://iuis.org/>

News/Events [Selected]

[19th International Congress of Immunology](#)

Vienna, August 17-22, 2025.

IVAC [to 22 Mar 2025]

<https://www.jhsph.edu/research/centers-and-institutes/ivac/index.html>

Updates; Events

No new digest content identified.

IVI [to 22 Mar 2025]

<http://www.ivi.int/>

IVI News & Announcements

[Helen Rees, Dominique Limet, and Nanette Cocero set to serve on the International Vaccine Institute's Board of Trustees in 2026](#)

March 18, 2025

Johns Hopkins Center for Health Security [to 22 Mar 2025]

<https://centerforhealthsecurity.org/newsroom>

Center News [Selected]

No new digest content identified.

MSF/Médecins Sans Frontières_[to 22 Mar 2025]

<http://www.msf.org/>

Latest [Selected Announcements]

Tuberculosis

Countries and donors must sustain investment in fight against tuberculosis in ch...

Press Release 20 Mar 2025

Malnutrition

MSF warns of a crisis as the numbers of malnourished children rise in Yemen

Press Release 19 Mar 2025

Malnutrition

Yemen's rising tide of malnutrition: seasonal trends 2022-2024

Report 19 Mar 2025

National Academy of Medicine - USA [to 22 Mar 2025]

<https://nam.edu/programs/>

News [Selected]

No new digest content identified.

National Academies-Sciences-Engineering-Medicine [NASEM]- USA [to 22 Mar 2025]

<https://www.nationalacademies.org/newsroom>

News

Trading Secrets: What Brain Science and AI Can Learn from Each Other

Due to the rapid rise and impact of artificial intelligence (AI) tools such as ChatGPT, ClaudeAI, and DeepSeek over the past several years, the National Academies' Forum on Neuroscience and Nervous System Disorders (Neuroscience Forum) set out to explore how knowledge about the brain could potentially shape better AI models, and, conversely, how AI models might help us learn more about the brain.

Date - 2025-03-19

Type - Program News

NIH [to 22 Mar 2025]

<http://www.nih.gov/>

News Releases

No new digest content identified.

PATH [to 22 Mar 2025]

<https://www.path.org/media-center/>

Newsroom [Selected]

Bivalent HPV vaccine Cecolin® demonstrates strong safety and immunogenicity in low- and middle-income country populations and in various dosing schedules

Results from a Phase 3 clinical study of Inovax's WHO prequalified vaccine can help expand access globally and give countries another option for affordable, sustainable HPV vaccine.

March 20, 2025

Sabin Vaccine Institute [to 22 Mar 2025]

<https://www.sabin.org/press/>

Latest News & Press Releases

No new digest content identified.

UNAIDS [to 22 Mar 2025]

<http://www.unaids.org/en>

News, Stories, Updates

Press Statement

World Tuberculosis Day: unite, invest and deliver to end TB

GENEVA, 21 March 2025—Tuberculosis (TB) and HIV are intricately linked, and they present profound challenges for global health. In 2023, 1.25 million people lost their lives to TB, including 161 000 people living with HIV. As the leading life threatening comorbidity of HIV infection, TB accounted for nearly one third of all deaths among people living with HIV in 2023...

Feature Story

Debt crisis threatens progress in the response to AIDS

20 March 2025

The significant health progress made over the past decade in Central, Eastern, Southern and West Africa—where many countries were on track to ending their AIDS epidemics—is now at risk of being reversed due to inadequate financing. One of the major causes of the funding shortfall is rising debts.

Feature Story

Impact of US funding cuts on the global AIDS response – 17 March 2025 update

19 March 2025

UNICEF [to 22 Mar 2025]

<https://www.unicef.org/media/press-releases>

Latest press releases, news notes and statements [Selected]

Press release 21 March 2025

As new school year starts in Afghanistan, almost 400,000 more girls deprived of their right to education, bringing total to 2.2 million

NEW YORK, 22 March 2025 - "As a new school year begins in Afghanistan, it marks three years since the start of the ban on girls' secondary education. This decision continues to harm the future of millions of Afghan girls. If this ban persists until 2030, over four million girls will have been deprived of their rig...

Remarks 21 March 2025

UNICEF Deputy Executive Director, Kitty van der Heijden Palais Briefing on Ethiopia, Nigeria and the global funding crisis

GENEVA/ABUJA, 21 March 2025 – "Good morning. It is good to be with you today. "In the last 25 years, we have made significant progress in tackling the global malnutrition crisis for children. Since the year 2000, the number of stunted children has decreased by 55 million, or one third. In 2024, UNICEF and our part...

Press release 21 March 2025

UNICEF condemns looting of life-saving supplies for children from Al Bashair hospital in Khartoum State

NEW YORK/PORT SUDAN, Sudan, 21 March 2025 – UNICEF condemns in the strongest possible terms the looting of vital humanitarian supplies—intended to save the lives of malnourished children and provide critical healthcare to mothers and newborns from Al Bashair Hospital in Jabal Awlia, Khartoum. The looting, which in...

Press release 19 March 2025

[UNICEF Goodwill Ambassador Millie Bobby Brown meets adolescent girls in Brazil and champions their rights](#)

SÃO PAULO/NEW YORK, 19 March 2025 – UNICEF Goodwill Ambassador Millie Bobby Brown met adolescent girls and young children while in São Paulo, Brazil, this week, to hear about their lives, the challenges they face, and how they are pursuing their dreams. During the visit, the Emmy-nominated actress – who earlier th...

Statement 18 March 2025

[Statement by UNICEF Executive Director Catherine Russell on the attacks in Gaza](#)

NEW YORK, 18 March 2025 – “Reports and images emerging from the Gaza Strip following today’s attacks are beyond horrifying. Hundreds of people have reportedly been killed, including more than 130 children, representing one of the largest single-day child death toll in the last year. “Some of the strikes reportedly...

Statement 16 March 2025

[Palestinian children remain deprived of the most essential supplies and services](#)

EAST JERUSALEM/THE GAZA STRIP, 16 March 2025 – “I have just concluded a four-day mission to the West Bank and the Gaza Strip. The situation is extremely concerning. “Far too often, children in the State of Palestine are the victims of this relentless conflict. Nearly all of the 2.4 million children living across t...

Unitaid [to 22 Mar 2025]

<https://unitaid.org/>

Featured News

News releases

[Unitaid and partners expand Africa’s first regional oxygen production network into Tanzania](#)

20 March 2025

News releases

[Japan partners with Unitaid to strengthen global health efforts for women and children](#)

19 March 2025

Vaccine Equity Cooperative [nee Initiative] [to 22 Mar 2025]

<https://vaccineequitycooperative.org/news/>

News

No new digest content identified.

Vaccination Acceptance & Demand Initiative [Sabin] [to 22 Mar 2025]

<https://www.vaccineacceptance.org/>

News

[10 Days From Marburg Outbreak Declaration to Vaccination: A High-Level Timeline](#)

March 11, 2025

Vaccine Confidence Project [to 22 Mar 2025]

<http://www.vaccineconfidence.org/>

News, Research and Reports

No new digest content identified.

Vaccine Education Center – Children’s Hospital of Philadelphia [to 22 Mar 2025]

<http://www.chop.edu/centers-programs/vaccine-education-center>

News

No new digest content identified.

Wellcome Trust [to 22 Mar 2025]

<https://wellcome.org/news/all>

News. Opinion, Reports

Explainer

[Will climate change lead to more fungal infections?](#)

22 March 2025 7-minute read

The Wistar Institute [to 22 Mar 2025]

<https://www.wistar.org/news/press-releases>

Press Releases

March 21, 2025

[Scientists Demonstrate Pre-clinical Proof of Concept for Next-Gen DNA Delivery Technology](#)

PHILADELPHIA — (March 21, 2025) — Scientists in The Wistar Institute lab of David B. Weiner, Ph.D., in collaboration with scientists in the laboratory of Norbert Pardi, Ph.D., at the University of Pe...

March 20, 2025

[The Wistar Institute Appoints Three New Members to its Board of Trustees](#)

Wistar welcomes Charles B. Cairns, M.D., Catherine Creese, and Carolyn Magill to the Board of Trustees

World Bank [to 22 Mar 2025]

<http://www.worldbank.org/en/news/all>

All News [Selected]

No new digest content identified.

WFPHA: World Federation of Public Health Associations [to 22 Mar 2025]

<https://www.wfpha.org/>

Blog, Events

No new digest content identified.

World Medical Association [WMA] [to 22 Mar 2025]

<https://www.wma.net/news-press/press-releases/>

Press Releases

No new digest content identified.

World Organisation for Animal Health [OIE] [to 22 Mar 2025]

<https://www.oie.int/>

Press Releases, Statements

Article

Controlling the cross-border spread of livestock diseases

While many countries are engaged in eradicating peste des petits ruminants (PPR) by 2030 and controlling the spread and impact of foot and mouth disease (FMD), their spread to previously disease-free areas in the world threatens livestock and human livelihoods, stressing the need for more surveillance and coordinated regional strategies.

[Undated]

.....
.....

ARM [Alliance for Regenerative Medicine] [to 22 Mar 2025]

<https://alliancerm.org/press-releases/>

Selected Press Releases

No new digest content identified.

BIO [to 22 Mar 2025]

<https://www.bio.org/press-releases>

Press Releases

No new digest announcements identified.

DCVMN – Developing Country Vaccine Manufacturers Network [to 22 Mar 2025]

<http://www.dcvmn.org/>

News; Upcoming events

No new digest announcements identified.

ICBA – International Council of Biotechnology Associations [to 22 Mar 2025]

<https://internationalbiotech.org/news/>

News

No new digest announcements identified.

IFPMA [to 22 Mar 2025]

<https://ifpma.org/>

News, Statements [Selected]

Position paper

Toolkit 4 Mar 2024

Our Ethos in Action – Decision-Making Framework Toolkit

IFPMA has developed a Five-Phase Decision-Making Framework, grounded in the IFPMA Ethos or value system, to help companies make decisions that balance business objectives and ethical considerations to meet patient needs and the expectations of the medical community, regulators, and society.

International Alliance of Patients' Organizations – IAPO [to 22 Mar 2025]

<https://www.iapo.org.uk/news>

Press and media [Selected]

No new digest announcements identified.

International Generic and Biosimilar Medicines Association [IGBA]

<https://www.igbamedicines.org/>

News

No new digest announcements identified.

PhRMA [to 22 Mar 2025]

<http://www.phrma.org/>

Press Releases

No new digest announcements identified.

.....
.....

Vaccines/Therapeutics/Medicines – Selected Developer/Manufacturer Announcements

AstraZeneca

Press Releases

Latest

[AstraZeneca to invest \\$2.5 billion in new global strategic R&D centre, biotech agreements and manufacturing in Beijing](#)

21 March 2025

PUBLISHED 21 March 2025

:: AstraZeneca is establishing a new global strategic R&D centre in Beijing, its second in China and sixth worldwide

:: Investment includes biotech agreements with Harbour BioMed, Syneron Bio and BioKangtai

[AstraZeneca to acquire EsoBiotec to advance cell therapy ambition](#)

17 March 2025

:: Acquisition includes world-leading in vivo delivery platform with potential to transform cell therapy

Bavarian Nordic

Latest News - No new digest content identified.

Bharat Biotech

Press Releases - No new digest announcements identified

BioCubaFarma – Cuba

Últimas Noticias - No new digest announcements identified

Biological E

News - No new digest announcements identified

BioNTech

Press Releases - No new digest announcements identified.

Boehringer

Press Releases - No new digest announcements identified.

CanSinoBIO

News - Website not responding at inquiry

CIGB

Latest News - No new digest announcements identified.

CinnaGen

Recent News - No new digest announcements identified.

Clover Biopharmaceuticals – China

News - No new digest announcements identified.

Curevac

News - No new digest announcements identified.

Gamaleya National Center/Sputnik

Latest News and Events - No new digest announcements identified [Last: 09 Nov 2020]

<https://sputnikvaccine.com/> - No new digest announcements identified [Last: 31 Aug 2022]

GSK

Press releases for media - No new digest announcements identified.

EuBiologics, S Korea

News - No new digest announcements identified.

IMBCAMS, China

Home - Website not responding at inquiry.

JNJ Innovative Medicine [Janssen]

Press Releases

Newsroom

Johnson & Johnson Increases U.S. Investment to More than \$55 Billion Over the Next Four Years

March 21, 2025 United States

:: Investment builds on almost 140-year legacy of improving and saving lives and supporting American jobs

:: Includes four planned new manufacturing facilities, with ground-breaking today in North Carolina on \$2 billion+ facility

:: Total Company U.S. economic impact estimated to be more than \$100 billion per year

Merck

News releases - No new digest announcements identified

Moderna

Press Releases - No new digest announcements identified

Nanogen

News - No new digest announcements identified

Novartis

News - No new digest announcements identified.

Novavax

Press Releases - No new digest announcements identified

Pfizer

Recent Press Releases - No new digest announcements identified.

R-Pharm

<https://rpharm-us.com/index.php>

[No news or media page identified]

Sanofi Pasteur

Press Releases - No new digest announcements identified.

Serum Institute

News & Announcements - No new digest announcements identified.

Sinopharm/WIBPBIBP

News - No new digest announcements identified.

Sinovac

Press Releases - No new digest announcements identified.

SK Biosciences

Press Releases - No new digest announcements identified.

Takeda

Newsroom - No new digest announcements identified.

Valneva

Press Releases - No new digest announcements identified.

Vector State Research Centre of Virology and Biotechnology

Home - [Website not responding [404 error]]

WestVac Biopharma

Media - No new digest announcements identified.

Zhifei Longcom, China

[Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.]

Website [No News/Announcements page identified]

.....
.....

Contents [click to move among sections]

:: [Milestones, Perspectives](#)

:: [WHO](#)

:: [Organization Announcements](#)

[:: Journal Watch](#)
[:: Pre-Print Servers](#)

.....
.....

Journal Watch

Vaccines and Global Health: The Week in Review continues its weekly scanning of key peer-reviewed journals to identify and cite articles, commentary and editorials, books reviews and other content supporting our focus on vaccine ethics and policy. Journal Watch is not intended to be exhaustive, but indicative of themes and issues the Center is actively tracking. We selectively provide full text of some editorial and comment articles that are specifically relevant to our work. Successful access to some of the links provided may require subscription or other access arrangement unique to the publisher.

If you would like to suggest other journal titles to include in this service, please contact David Curry at: david.r.curry@centerforvaccineethicsandpolicy.org

AJOB Empirical Bioethics

Volume 16, 2025 Issue 1

<https://www.tandfonline.com/toc/uabr21/current>

[Reviewed earlier]

AMA Journal of Ethics

March 2025 Volume 27, Number 3: E167-236

<https://journalofethics.ama-assn.org/issue/regret-moral-psychology-surgical-professionalism>

Issue Theme: Regret in the Moral Psychology of Surgical Professionalism

Along a physician's training path to becoming a surgeon, there are few, if any, formal or structured opportunities to reflect upon regret experiences. But the influences regret can have in surgeons' practices is worth considering, given that some patients suffer poor outcomes despite surgeons' long-term training, sound decision-making, competent practice, best efforts, and good intentions. This theme issue investigates regret as an expression of a surgeon's moral psychological development and their deep internalization of their capacity to harm. This theme issue also considers how we should regard regret and its kindred moral emotions—loss, grief, remorse, shame, guilt—in surgical life, training, and practice.

[Reviewed earlier]

American Journal of Human Genetics

Mar 06, 2025 Volume 112 Issue 3 p457-724

<https://www.cell.com/ajhg/current>

This month in The Journal

Alyson B. Barnes, Sara B. Cullinan

Publication of the 2023 NASEM report sparked discussions on the use of population descriptors in genetics and genomics research. Experts have offered guidance to researchers in various sub-fields, but little guidance has been provided for clinical laboratory settings. In this issue, Hatchell et al. build on their experience in clinical genomics laboratories to provide insight into the relevance of both conventional and ancestry-based population descriptors for genetic testing and reporting. There are advantages and disadvantages to the use of both types of descriptors.

[Reviewed earlier]

American Journal of Infection Control

March 2025 Volume 53 Issue 3 p285-414

<http://www.ajicjournal.org/current>

[Reviewed earlier]

American Journal of Preventive Medicine

March 2025 Volume 68 Issue 3 p429-644

<https://www.ajpmonline.org/current>

[Reviewed earlier]

American Journal of Public Health

March 2025 115(3)

<http://ajph.aphapublications.org/toc/ajph/current>

[Reviewed earlier]

American Journal of Tropical Medicine and Hygiene

Volume 112 (2025): Issue 2 (Feb 2025)

<https://www.ajtmh.org/view/journals/tpmd/112/2/tpmd.112.issue-2.xml>

[Reviewed earlier]

Annals of Internal Medicine

March 2025 Volume 178, Issue 3

<https://www.acpjournals.org/toc/aim/current>

Original Research

[Effectiveness of the 2023-to-2024 XBB.1.5 COVID-19 Vaccines Over Long-Term Follow-up A Target Trial Emulation](#)

George N. Ioannou, BMBCCh, MS, Kristin Berry, PhD, Nallakkandi Rajeevan, PhD, Yuli Li, MS, [... et al.](#)

Pages:348–359

Artificial Intelligence – An International Journal

Volume 340 March 2025

<https://www.sciencedirect.com/journal/artificial-intelligence/vol/340/suppl/C>

[New issue; No digest content identified]

BMC Cost Effectiveness and Resource Allocation

<http://resource-allocation.biomedcentral.com/>

(Accessed 22 Mar 2025)

[No new digest content identified]

BMC Health Services Research

<http://www.biomedcentral.com/bmchealthservres/content>

(Accessed 22 Mar 2025)

[Costs of delivering COVID-19 vaccine in Botswana during the height of the pandemic: a retrospective study](#)

The development, distribution and delivery of COVID-19 vaccines following the outbreak of the global coronavirus pandemic in February 2020 is the largest global immunization action in history. To assist with p...

Authors: Kelsey Vaughan, Onalenna T. Mokena, Goabaone Rankgoane-Pono, Moses Keetile and Ulla Kou Griffiths

Citation: *BMC Health Services Research* 2025 25:405

Content type: Research Published on: 19 March 2025

BMC Infectious Diseases

<http://www.biomedcentral.com/bmcinfectdis/content>

(Accessed 22 Mar 2025)

[Regional difference on rotavirus vaccine coverage in children with diarrhea in Mozambique, before and during COVID-19 pandemic: a cross-sectional analysis](#)

Immunization coverage is a global concern for the Immunization Agenda 2030 due to the Coronavirus disease (COVID-19) pandemic. Prior to the pandemic, Mozambique had a positive impact on reducing all-cause diar...

Authors: Marta Cassocera, Adilson Fernando Loforte Bauhofer, Assucênio Chissaque, Benilde Munlela, Esperança Guimarães, Telma Isaías, Carolina Conjo, Braiton Maculuve, Sérgio Chicumbe and Nilsa de Deus

Citation: *BMC Infectious Diseases* 2025 25:382

Content type: Research Published on: 19 March 2025

BMC Medical Ethics

<http://www.biomedcentral.com/bmcmedethics/content>

(Accessed 22 Mar 2025)

[Ethical challenges in conducting research in low and middle income setting during public health emergencies: a qualitative evidence of a COVID-19 pandemic: the experience of Iran](#)

Every minute during an epidemic is important and research in such conditions is for the benefit of the society. Considering that identifying experiences is a way to prevent repeated mistakes and prepare people...

Authors: Ehsan Shamsi-Gooshki, Alireza Parsapoor and Soolmaz Moosavi

Citation: *BMC Medical Ethics* 2025 26:38

Content type: Research Published on: 17 March 2025

[A scoping review of human genetic resources management policies and databases in high- and middle-low-income countries](#)

This review examines global human genetic resources management, focusing on genetic data policies and repositories in high- and middle-low-income countries.

Authors: Hongwei Liu, Yin Liu, Yanyan Zhao, Yingqi Ma, Qiong Chen, Huifang Xu, Xiaoyang Wang, Xiaoli Guo, Hong Wang, Zelong Chen, Shaokai Zhang and Binbin Han

Citation: *BMC Medical Ethics* 2025 26:37

Content type: Systematic Review Published on: 15 March 2025

[Balancing benefits and burdens: a systematic review on ethical and social dimensions of gene and cell therapies for hereditary blood diseases](#)

Sickle cell disease (SCD) and Diamond-Blackfan anemia syndrome (DBAS) are two hereditary blood diseases that present significant challenges to patients, their caregivers, and the healthcare system. Both condit...

Authors: L. C. van Hooff, E.-M. Merz, A. S. Kidane Gebremeskel, J. A. de Jong, G. L. Burchell and J. E. Lunshof
Citation: BMC Medical Ethics 2025 26:36
Content type: Systematic Review Published on: 14 March 2025

BMC Medicine

<http://www.biomedcentral.com/bmcmed/content>
(Accessed 22 Mar 2025)
[No new digest content identified]

BMC Pregnancy and Childbirth

<http://www.biomedcentral.com/bmcpregnancychildbirth/content>
(Accessed 22 Mar 2025)
[No new digest content identified]

BMC Public Health

<http://bmcpublichealth.biomedcentral.com/articles>
(Accessed 22 Mar 2025)

[COVID-19 vaccination uptake in Ohio: analyzing the difference between metro and non-metro residents](#)

The COVID-19 pandemic resulted in the rapid development and distribution of vaccines as a critical strategy to control the spread of the virus. This paper explores COVID-19 vaccine uptake in the state of Ohio,...

Authors: Maya Patel, Yevgeniya Gokun, Cecilia DeGraffinreid, Chasity Washington, Ryan D. Baltic, Matthew D. Ringel and Electra D. Paskett

Citation: *BMC Public Health* 2025 25:1103

Content type: Research Published on: 22 March 2025

[Vaccine hesitancy and acceptance among hemodialysis patients: a cross-sectional study in Turkey](#)

Vaccine hesitancy remains a significant issue threatening public health. The study aimed to determine the vaccination status of patients undergoing hemodialysis for chronic kidney disease and to analyze their ...

Authors: Fatma Betül Sayan Kaya, Ayşe Rumeysa Doğruyol, Hakkı Öztürk, Sevgi Canbaz and Meryem Merve Ören Çelik

Citation: *BMC Public Health* 2025 25:1037

Content type: Research Published on: 18 March 2025

[COVID-19 vaccine acceptance and hesitancy in Cameroon: a systematic review and meta-analysis](#)

The development of effective vaccines was a promising tool for ending the pandemic. However, the success of a vaccination programme hinges on achieving substantial community acceptance. In Cameroon, numerous s...

Authors: Fabrice Zobel Lekeumo Cheuyem, Adidja Amani, Iyawa Clarisse Alma Nkodo, Lionel Bethold Keubou Boukeng, Michel Franck Edzamba, Ariane Nouko, Edwige Omona Guissana, Christelle Sandrine Ngos, Chabeja Achangwa and Christian Mouangue

Citation: *BMC Public Health* 2025 25:1035

Content type: Systematic Review Published on: 17 March 2025

Longitudinal association between parents' reported vaccination program preferences and children's actual immunization patterns in Shanghai, China

As China expands its national immunization program, it is essential to understand parents' beliefs about pediatric vaccination programs and the translation into actual vaccination decision-making for their children...

Authors: Zhuoying Huang, Mengdi Ji, Matthew L. Boulton, Jia Ren, Xiaodong Sun and Abram L. Wagner

Citation: *BMC Public Health* 2025 25:999

Content type: Research Published on: 14 March 2025

BMC Research Notes

<http://www.biomedcentral.com/bmcresnotes/content>

(Accessed 22 Mar 2025)

[No new digest content identified]

BMJ Evidence-Based Medicine

April 2025 - Volume 30 - 2

<https://ebm.bmj.com/content/30/2>

[New issue; No digest content identified]

BMJ Global Health

March 2025 - Volume 10 - 3

<https://gh.bmj.com/content/10/3>

Commentary

Can solidarity in global health curb the next outbreak? A commentary on mpox (7 March, 2025)

Natalie Tegama, Julian Natukunda, Imogen Alexandra Fiona Brown, Caesar Alimisnya Atuire

Original research

Public-targeted interventions addressing antimicrobial resistance and antibiotic use in Sub-Saharan Africa: a scoping review (21 March, 2025)

Winifred Maduko, Emmanuel Olamijuwon, Mike Kesby, Jo Mhairi Hale

Regional, subregional and country-level full vaccination coverage in children aged 12–23 months for 34 countries in sub-Saharan Africa: a global analysis using Demographic and Health Survey data (15 March, 2025)

David Jean Simon, Vénunyé Claude Kondo Tokpovi, Kassoum Dianou, Osaretin Christabel Okonji, Ann Kiragu, Comfort Z Olorunsaiye, Emmanuel Juakaly Wayisovia, Adama Ouedraogo, Patrice Ngangue, Habib Tchoubou Foba, Serge Madjou

Coverage, timeliness of measles immunisation and its predictors in Pakistan: an analysis of 6.2 million children enrolled in the Provincial Electronic Immunisation Registry (3 March, 2025)

Manaksha Memon, Danya Arif Siddiqi, Vijay Kumar Dharma, Mubarak Taighoon Shah, Sundus Iftikhar, Hamidreza Setayesh, Subhash Chandir

Practice

Strengthening global partnerships for sustainable sickle cell disease care: insights from SickleInAfrica at the 77th United Nations General Assembly and the US-Africa Leaders' Summit (13 March, 2025)

Irene Kida Minja, Siana Nkya, Daima Bukini, Nesia Mahenge, Upendo Masamu, Janeth Manongi, Josephine Mgaya, Frank Mtiye, Malula Nkanyemka, Eka Patricia Kisali, Isihaka Mwinchande Mahawi, Aisha Rifai, Agnes Jonathan, Victoria Nembaware, Mario Jonas, Nicola Mulder, Ruth Namazi, Deogratius Munube, Vivian Paintsil, Raphael Zozimus Sangeda, Hans Ackerman, Ruhl Parker, Fred Stephan Sarfo, Aldiouma Guindo, Obiageli Eunice Nnodu, Emmanuel Balandya, Sarah Kiguli, Catherine Chunda-Liyoka, Patience Kuona, Emmanuel Peprah, Appolinary Kamuhabwa, Julie Makani

Bulletin of the World Health Organization

2025 Mar 1; 103(3)

<https://www.who.int/publications/journals/bulletin/>

[Reviewed earlier]

Cell

Mar 06, 2025 Volume 188 Issue 5 p1175-1456

<https://www.cell.com/cell/current>

[Reviewed earlier]

Child Care, Health and Development

Volume 51, Issue 2 March 2025

<https://onlinelibrary.wiley.com/toc/13652214/current>

[Reviewed earlier]

Clinical Pharmacology & Therapeutics

Volume 117, Issue 3 Pages: 599-857 March 2025

<https://ascpt.onlinelibrary.wiley.com/toc/15326535/current>

[Reviewed earlier]

Clinical Therapeutics

March 2025 Volume 47 Issue 3 p179-248

<http://www.clinicaltherapeutics.com/current>

[Reviewed earlier]

Clinical Trials

Volume 22 Issue 1, February 2025

<https://journals.sagepub.com/toc/ctja/22/1>

[Reviewed earlier]

Conflict and Health

<http://www.conflictandhealth.com/>

[Accessed 22 Mar 2025]

[No new digest content identified]

Contemporary Clinical Trials

Volume 150 March 2025

<https://www.sciencedirect.com/journal/contemporary-clinical-trials/vol/150/suppl/C>
[Reviewed earlier]

The CRISPR Journal

Volume 8, Issue 1 / February 2025
<https://www.liebertpub.com/toc/crispr/8/1>
[Reviewed earlier]

Current Genetic Medicine Reports

Volume 13, Issue 1 December 2025
<https://link.springer.com/journal/40142/volumes-and-issues/13-1>
[Reviewed earlier]

Current Medical Research and Opinion

Volume 41, Issue 1 2025
<https://www.tandfonline.com/toc/icmo20/current>
[Reviewed earlier]

Current Opinion in Infectious Diseases

February 2025 - Volume 38 - Issue 1
<https://journals.lww.com/co-infectiousdiseases/pages/currenttoc.aspx>
[Reviewed earlier]

Current Protocols in Human Genetics

<https://currentprotocols.onlinelibrary.wiley.com/journal/19348258>
[Accessed 22 Mar 2025]
[No new digest content identified]

Developing World Bioethics

Volume 25, Issue 1 Pages: 1-79 March 2025
<https://onlinelibrary.wiley.com/toc/14718847/current>
[Reviewed earlier]

Development in Practice

Volume 34, Issue 6, 2024
<https://www.tandfonline.com/toc/cdip20/34/6>
[Reviewed earlier]

Development Policy Review

Volume 43, Issue 2 March 2025
<https://onlinelibrary.wiley.com/toc/14677679/current>
[Reviewed earlier]

Disaster Medicine and Public Health Preparedness

Volume 19 - 2025

<https://www.cambridge.org/core/journals/disaster-medicine-and-public-health-preparedness/latest-issue>

[New issue; No digest content identified]

Disasters

Volume 49, Issue 1 January 2025

<https://onlinelibrary.wiley.com/toc/14677717/2025/49/1>

[Reviewed earlier]

EMBO Reports

Volume 26 Issue 5 10 March 2025

<https://www.embopress.org/toc/14693178/current>

[Reviewed earlier]

Emerging Infectious Diseases

Volume 31, Number 2—February 2025

<http://wwwnc.cdc.gov/eid/>

[Reviewed earlier]

Epidemics

Volume 50 March 2025

<https://www.sciencedirect.com/journal/epidemics/vol/50/suppl/C>

[New issue; No digest content identified]

Epidemiology and Infection

Volume 153 - 2025

<https://www.cambridge.org/core/journals/epidemiology-and-infection/latest-issue>

[Reviewed earlier]

Ethics & Human Research

Volume 47, Issue 1 Pages: 1-45 January–February 2025

<https://onlinelibrary.wiley.com/toc/25782363/current>

Moral distress in clinical research • Research with incarcerated and homeless women

[Reviewed earlier]

Ethics & International Affairs

Volume 38 - Issue 3 - Fall 2024

<https://www.cambridge.org/core/journals/ethics-and-international-affairs/latest-issue>

[Reviewed earlier]

Ethics, Medicine and Public Health

Volume 32 2024

<https://www.sciencedirect.com/journal/ethics-medicine-and-public-health/vol/32/suppl/Cc>
[Reviewed earlier]

The European Journal of Public Health

Volume 35, Issue 1, February 2025

<https://academic.oup.com/eurpub/issue/35/1>

[Reviewed earlier]

Expert Review of Vaccines

Volume 24, 2025 Issue 1

<https://www.tandfonline.com/toc/ierv20/current>

[Reviewed earlier]

Foreign Affairs

January/February 2025

<https://www.foreignaffairs.com/issues/2025/104/1>

Special Section

Will Trump Change the World?

Forum for Development Studies

Volume 51, 2024 - Issue 3

<http://www.tandfonline.com/toc/sfds20/current>

[Reviewed earlier]

Frontiers in Medicine

<https://www.frontiersin.org/journals/medicine/volumes?volume-id=1463>

[Accessed 22 Mar 2025]

[No new digest content identified]

Gene Therapy – Nature

Volume 32 Issue 1, January 2025

<https://www.nature.com/qt/volumes/32/issues/1>

[Reviewed earlier]

Genetics in Medicines

Volume 27, Issue 3 March 2025

<https://www.sciencedirect.com/journal/genetics-in-medicine/vol/27/issue/3>

[Reviewed earlier]

Genome Medicine

<https://genomemedicine.biomedcentral.com/articles>

[Accessed 22 Mar 2025]

[No new digest content identified]

Global Health Action

Volume 18, Issue 1 (2025)

<https://www.tandfonline.com/toc/zgha20/current?nav=tocList>

[Reviewed earlier]

Global Health: Science and Practice (GHSP)

Vol. 12, No. 6 December 20, 2024

<http://www.ghspjournal.org/content/current>

[Reviewed earlier]

Global Legal Monitor & Legal Reports – Library of Congress/USA

<https://www.loc.gov/collections/global-legal-monitor/>

https://www.loc.gov/books/?q=legal+reports&fa=partof%3Alegal+reports+%28publications+of+the+law+library+of+congress%29&sb=date_desc

[Accessed 22 Mar 2025]

[No new digest content identified]

Global Public Health

Volume 20, Issue 1 (2025)

<http://www.tandfonline.com/toc/rgph20/current>

[Reviewed earlier]

Globalization and Health

<http://www.globalizationandhealth.com/>

[Accessed 22 Mar 2025]

[No new digest content identified]

Health and Human Rights

Volume 26, Issue 2, December 2024

<https://www.hhrjournal.org/volume-26-issue-2-december-2024/>

Special Section: Distress Migration and the Right to Health

[Reviewed earlier]

Health Economics, Policy and Law

Volume 19 - Issue 4 - October 2024

<https://www.cambridge.org/core/journals/health-economics-policy-and-law/latest-issue>

[Reviewed earlier]

Health Policy and Planning

Volume 40, Issue 2, March 2025

<https://academic.oup.com/heapol/issue/40/2>

[Reviewed earlier]

Health Research Policy and Systems

<http://www.health-policy-systems.com/content>

[Accessed 22 Mar 2025]

[No new digest content identified]

Human Gene Therapy

Volume 36, Issue 5-6 / March 2025

<https://www.liebertpub.com/toc/hum/36/5-6>

[Reviewed earlier]

Humanitarian Practice Network

<https://odihpn.org/>

Featured Publications

[No new digest content identified]

Human Vaccines & Immunotherapeutics (formerly Human Vaccines)

Volume 20 Issue 1, 2024

<https://www.tandfonline.com/toc/khvi20/20/1?nav=tocList>

Selected Content

[Reviewed earlier]

Immunity

Feb 11, 2025 Volume 58 Issue 2 p265-514

<https://www.cell.com/immunity/current>

[Reviewed earlier]

Infectious Agents and Cancer

<http://www.infectagentscancer.com/>

[Accessed 22 Mar 2025]

[No new digest content identified]

Infectious Diseases of Poverty

<http://www.idpjournal.com/content>

[Accessed 22 Mar 2025]

[No new digest content identified]

International Health

Volume 17, Issue 2, March 2025

<https://academic.oup.com/inthealth/issue/17/2>

[Reviewed earlier]

International Human Rights Law Review

Volume 13 (2024): Issue 2 (Dec 2024)

<https://brill.com/view/journals/hrlr/13/2/hrlr.13.issue-2.xml>

[Reviewed earlier]

International Journal of Community Medicine and Public Health

Vol. 12 No. 2 (2025): February 2025

<https://www.ijcmph.com/index.php/ijcmph/issue/view/121>

[Reviewed earlier]

International Journal of Epidemiology

Volume 54, Issue 1, February 2025

<https://academic.oup.com/ije/issue/54/1>

[Reviewed earlier]

International Journal of Human Rights in Healthcare

Volume 18 Issue 1 2025

<https://www.emerald.com/insight/publication/issn/2056-4902/vol/18/iss/1>

Table of contents

[New issue; No digest content identified]

JAMA

March 18, 2025, Vol 333, No. 11, Pages 921-1014

<https://jamanetwork.com/journals/jama/currentissue>

Viewpoint

US Science in Peril

Rochelle P. Walensky, MD, MPH; Loren D. Walensky, MD, PhD

JAMA. 2025;333(11):933-934. doi:10.1001/jama.2025.1929

This Viewpoint discusses the importance of federal funding of biomedical research from the National Institutes of Health to scientific discovery, advancements in individual and public health, and the support of the US' community of scientists.

Editorial

The Value of Academic Health Research

Sandro Galea, MD, DrPH; Kirsten Bibbins-Domingo, PhD, MD, MAS

Reaffirming the JAMA Network Commitment to the Health of Patients and the Public

Kirsten Bibbins-Domingo, PhD, MD, MAS; Robert O. Bonow, MD, MS; Neil M. Bressler, MD; Linda Brubaker, MD, MS; Dimitri Christakis, MD, MPH; Stacy L. Christiansen, MA; Gregory Curfman, MD; Mary L. (Nora) Disis, MD; Annette Flanagin, RN, MA; Sandro Galea, MD, DrPH; Sharon K. Inouye, MD, MPH; S. Andrew Josephson, MD; Melina R. Kibbe, MD; Tracy A. Lieu, MD, MPH; Preeti N. Malani, MD, MSJ; Mary M. McDermott, MD; Christopher C. Muth, MD; Dost Öngür, MD, PhD; Hannah Park; Jay F. Piccirillo, MD; Eli N. Perencevich, MD, MS; Roy H. Perlis, MD, MSc; Joseph S. Ross, MD; Kanade Shinkai, MD, PhD; Kristin L. Walter, MD, MS

JAMA Health Forum

March 2025, Vol 6, No. 3

<https://jamanetwork.com/journals/jama-health-forum/issue>

[Reviewed earlier]

JAMA Pediatrics

March 2025, Vol 179, No. 3, Pages 228-356

<https://jamanetwork.com/journals/jamapediatrics/currentissue>

[New issue; No digest content identified]

JBI Evidence Synthesis

March 2025 - Volume 23 - Issue 3

<https://journals.lww.com/jbisrir/Pages/currenttoc.aspx>

[Reviewed earlier]

Journal of Adolescent Health

March 2025 Volume 76 Issue 3 p341-526

<https://www.jahonline.org/current>

[Reviewed earlier]

Journal of Artificial Intelligence Research

Vol. 82 (2025)

<https://www.jair.org/index.php/jair>

Contents

[New issue; No digest content identified]

Journal of Community Health

Volume 50, Issue 1 February 2025

<https://link.springer.com/journal/10900/volumes-and-issues/50-1>

[Reviewed earlier]

Journal of Current Medical Research and Opinion

...a peer-reviewed, international journal for the rapid publication of original research on new and existing drugs and therapies, and post-marketing investigations. Equivalence, safety and efficacy/effectiveness studies are especially encouraged.

Vol. 8 No. 01 (2025)

<https://www.cmro.in/index.php/jcmro/issue/view/91>

[Reviewed earlier]

Journal of Development Economics

Volume 173 March 2025

<https://www.sciencedirect.com/journal/journal-of-development-economics/vol/173/suppl/C>

[Reviewed earlier]

Journal of Empirical Research on Human Research Ethics

Volume 19 Issue 4-5, October–December 2024

<http://journals.sagepub.com/toc/jre/current>

[Reviewed earlier]

Journal of Epidemiology & Community Health

March 2025 - Volume 79 - 3

<https://jech.bmj.com/content/79/3>

[Reviewed earlier]

Journal of Evidence-Based Medicine

Volume 18, Issue 1 March 2025

<https://onlinelibrary.wiley.com/toc/17565391/current>

[Reviewed earlier]

Journal of Global Ethics

Volume 20, Issue 3 (2024)

<http://www.tandfonline.com/toc/rjge20/current>

Special Issue: 20th Anniversary Forum

[Reviewed earlier]

Journal of Health Care for the Poor and Underserved (JHCPU)

Volume 36, Number 1, February 2025

<https://muse.jhu.edu/issue/54278>

Table of Contents

[Reviewed earlier]

Journal of Immigrant and Minority Health

Volume 27, Issue 1 February 2025

<https://link.springer.com/journal/10903/volumes-and-issues/27-1>

[Reviewed earlier]

Journal of Immigrant & Refugee Studies

Volume 23, Issue 1 (2025)

<https://www.tandfonline.com/toc/wimm20/current>

[Reviewed earlier]

Journal of International Development

Volume 37, Issue 2 Pages: 1-619 March 2025

<https://onlinelibrary.wiley.com/toc/10991328/current>

[Reviewed earlier]

Journal of Medical Ethics

March 2025 - Volume 51 - 3

<http://jme.bmj.com/content/current>

[Reviewed earlier]

Journal of Patient-Centered Research and Reviews

Volume 11, Issue 3 (2024)
<https://institutionalrepository.aah.org/jpcrr/>
[Reviewed earlier]

The Journal of Pediatrics

Volume 277 February 2025
<https://www.sciencedirect.com/journal/the-journal-of-pediatrics/vol/277/suppl/C>
[Reviewed earlier]

Journal of Pharmaceutical Policy and Practice

Volume 18, 2025 Issue 1
<https://www.tandfonline.com/toc/jppp20/18/1?nav=tocList>
Article

From awareness to acceptance: understanding HPV and vaccine knowledge, attitudes and beliefs among university students in Punjab, Pakistan

Naveel Atif, Furqan Khurshid Hashmi, Usman Rashid Malik, Mohsin Ahmad Ghauri, Ali Hassan Gillani, Mukhtar Kadirhaz, Minghuan Jiang, Jie Chang & Yu Fang
Article: 2473023
Published online: 19 Mar 2025

Journal of Public Health Management & Practice

March/April 2025 - Volume 31 - Issue 2
<https://journals.lww.com/jphmp/pages/currenttoc.aspx>
[Reviewed earlier]

Journal of Public Health Policy

Volume 45, issue 4, December 2024
<https://link.springer.com/journal/41271/volumes-and-issues/45-4>
[Reviewed earlier]

Journal of the Royal Society – Interface

March 2025 Volume 22 Issue 224
<https://royalsocietypublishing.org/toc/rsif/current>
[Reviewed earlier]

Journal of Travel Medicine

Volume 32, Issue 2, March 2025
<https://academic.oup.com/jtm/issue>
[Reviewed earlier]

Journal of Virology

Volume 99 • Number 2 • February 2025
<http://jvi.asm.org/content/current>
[Reviewed earlier]

The Lancet

Mar 22, 2025 Volume 405 Number 10483 p951-1026, e6-e18

<https://www.thelancet.com/journals/lancet/issue/current>

Editorial

The demise of USAID: time to rethink foreign aid?

The Lancet

The US Agency for International Development (USAID) is no more. Marco Rubio, the US Secretary of State, has announced that 83% of programmes funded by USAID are to be ended, with the remainder to be absorbed by the State Department. Notwithstanding legal challenges, these decisions signal the end of an organisation that has brought crucial aid to millions globally. The move confirms the worst fears of the international community, coming 6 weeks after a pause on USAID's work that saw 5200 contracts cancelled, classified documents shredded, and life-saving aid halted. The Trump Administration's dismantling of USAID is a catastrophe for global health, the consequences of which will be felt for generations.

In the 2024 fiscal year, USAID disbursed US\$32·5 billion, with Ukraine, Jordan, and Ethiopia being the top recipients. \$8·9 billion went to health programmes and \$8·6 billion to humanitarian assistance. \$2·3 billion was devoted to fighting HIV/AIDS, tuberculosis, and malaria globally, and \$290 million to vaccine development and immunisation programmes. USAID has been a key supporter of the World Bank Group, the World Food Programme, and the Global Fund to Fight AIDS, Tuberculosis, and Malaria, driving progress towards the UN Sustainable Development Goals. Without USAID, the future of many global health programmes hangs in the balance, putting countless lives at risk.

There are clear moral arguments for USAID's work, but the organisation is not a charity. Founded in 1961 by President John F Kennedy, USAID has served as an important instrument of America's soft power, providing a countervailing view of the USA in many parts of the world where the country is known primarily for its military follies and exercises of hard power. Through investments in health, education, and democracy, USAID fostered diplomatic relationships and strengthened governance and peace, positioning the USA as a leader in international development and helping to safeguard the country's security. A vital part of what shapes the USA's global influence has been destroyed.

As countries such as the UK, France, and Germany also scale back their aid spending, the question now is: who or what can fill the void? The aid system is far from perfect. For years, critics have pointed to inherent flaws, arguing that aid sustains dependency instead of promoting long-term development. In many countries, aid displaces domestic resourcing, with billions lost to fraud, mismanagement, and corruption. Aid can impose bureaucracy on underfunded ministries of health, making effective management challenging, and frequently comes with political or economic conditions that reflect the needs of donors rather than recipients. This dependence and influence reinforces a neocolonial dominance of the Global North. Is there, therefore, an opportunity to rethink the global aid architecture, rather than replace it?

Aid is undoubtedly essential in some circumstances. The Global Health 2050 Lancet Commission argued that development assistance should focus on two broad purposes: first, direct support for basic services and disease control in countries with the least resources; and second, financing of global public goods to, for example, tackle antimicrobial resistance, prevent and respond to pandemics, and develop and deploy new health technologies. For many nations, however, discussions have long been taking place about how to create a more sustainable and self-reliant approach to financing health and development, including through increasing domestic spending. Strong regional health agencies and regional development banks have emerged, along with a push to diversify and localise supply chains for drugs and vaccines. The 2023 Lusaka Agenda calls for increasing investments in local health systems, strengthening local capacity, and developing accountability and transparency mechanisms to

monitor the use of domestic resources. On Feb 14, the African Union's High-Level meeting on Domestic Financing in Africa took place in Addis Ababa, where Oluremi Tinubu, First Lady of Nigeria, declared that "Africa cannot continue to rely solely on donor funding and foreign aid, which, although helpful, are often unpredictable and unsustainable".

That unpredictability is now painfully clear. The sweeping chaotic and ill-considered unilateral halt of global health programmes is no way to institute reforms. Change should be strategic, transparent, carefully implemented, and done in a spirit of support rather than imposition. Local expertise and resources should be centred in systems that empower nations to take charge of their development and health needs. The demise of USAID leaves no choice but to reconsider the broader landscape of foreign aid itself.

Articles

Mapping the global prevalence, incidence, and mortality of *Plasmodium falciparum* and *Plasmodium vivax* malaria, 2000–22: a spatial and temporal modelling study

Daniel J Weiss, et al.

Open Access

The Lancet Child & Adolescent Health

Mar 2025 Volume 9 Number 3 p151-210, e4-e9

<https://www.thelancet.com/journals/lanchi/issue/current>

[Reviewed earlier]

Lancet Digital Health

Mar 2025 Volume 7 Number 3 e167-e231

<https://www.thelancet.com/journals/landig/issue/current>

[Reviewed earlier]

Lancet Global Health

Mar 2025 Volume 13 Number 3 e372-e598

<https://www.thelancet.com/journals/langlo/issue/current>

[Reviewed earlier]

Lancet Infectious Diseases

Mar 2025 Volume 25 Number 3 p243-356, e114-e190

<https://www.thelancet.com/journals/laninf/issue/current>

[Reviewed earlier]

Lancet Public Health

Mar 2025 Volume 10 Number 3 e165-e263

<https://www.thelancet.com/journals/lanpub/issue/current>

[Reviewed earlier]

Lancet Respiratory Medicine

Mar 2025 Volume 13 Number 3 p189-288, e17-e19

<https://www.thelancet.com/journals/lanres/issue/current>

[Reviewed earlier]

Maternal and Child Health Journal

Volume 29, Issue 2 February 2025

<https://link.springer.com/journal/10995/volumes-and-issues/29-2>

[Reviewed earlier]

Medical Decision Making (MDM)

Volume 45 Issue 3, April 2025

<http://mdm.sagepub.com/content/current>

[New issue; No digest content identified]

The Milbank Quarterly

A Multidisciplinary Journal of Population Health and Health Policy

Volume 103, Issue 1 Pages: 1-241 March 2025

<https://onlinelibrary.wiley.com/toc/14680009/current>

Perspective

Open Access

Centering Equity in Evidence-Informed Decision Making: Theoretical and Practical Considerations

BOMI KIM HIRSCH, KIERSTEN FROBOM, GILLIAN GIGLIERANO, MICHAEL C. STEVENSON, MARJORY L. GIVENS

Pages: 11-31

First Published: 27 February 2025

Abstract

Policy Points

- The population health research field should develop a synthesized approach to evaluate evidence for an intervention's potential impact on equity.
- When empirical evidence is lacking, theory and frameworks should guide the equity assessments in four areas: 1) understanding historical context, meaning root causes of disparities and inequity; 2) understanding intervention design and intended beneficiaries; 3) understanding differential impact and intersectionality; and 4) understanding community context before implementing or scaling interventions.
- The synthesized approach of equity assessment better informs practitioners and policymakers in evidence-based decision making to advance equity.

Original Research

Open Access

Innovative Insurance to Improve US Patient Access to Cell and Gene Therapy

RENA M. CONTI, PATRICK DEMARTINO, JONATHAN GRUBER, ANDREW W. LO, YUTONG SUN, JACKIE WU

Pages: 32-51

First Published: 18 January 2025

Abstract

Policy Points

- Cell and gene therapies (CGTs) offer treatment for rare and oftentimes deadly disease, but their prices are high, and payers may seek to limit spending.

- Total annual costs of covering all existing and expected CGTs for the entire US population 2023–2035 to amount to less than \$20 per person and concentrate in commercial and state Medicaid plans.
- Reinsurance fees add to expected costs.
- Policies that improve coverage and affordability are needed to assure patient access to CGTs.

Molecular Therapy

Mar 05, 2025 Volume 33 Issue 3 p825-1304

<https://www.cell.com/molecular-therapy/current>

[Reviewed earlier]

Nature

Volume 639 Issue 8055, 20 March 2025

<https://www.nature.com/nature/volumes/638/issues/8055>

Editorial 18 Mar 2025

Vaccines save lives. Leaders must champion them

Attacks on vaccines and the cancellation of research into what causes vaccine hesitancy puts people in harm's way.

Measles is a highly contagious disease that can be fatal, particularly in young children. Nevertheless, every death it causes — some 107,500 in 2023, the latest year for which data are available — is avoidable. One invention has the power to wipe out the disease. And it is thanks to that invention — vaccines — that the World Health Organization has been able to declare 82 countries around the world as having eliminated measles.

One of those nations is the United States, but many fear it will not remain so for much longer. A dangerous measles outbreak is raging in Texas. It was detected in late January and, about a month later, an otherwise healthy but unvaccinated six-year-old died from the disease — the first person in a decade to lose their life to measles in the United States.

Measles is on the rise in almost every world region. In 2023, 57 countries around the globe experienced large or disruptive outbreaks, an increase from 36 in 2022. These outbreaks correspond with a decline in people getting vaccinated. In some cases, that decline coincides with active campaigns — often spearheaded by people with power and influence — communicating information about vaccines that is not in line with internationally accepted public-health advice.

We urge all leaders, for the good of their nations' health, not to ignore or contradict advice that is supported by a consensus of evidence from research. We urge policymakers to help boost people's confidence in vaccines, and not to undermine scientific and medical institutions or the process of research. At present, this leadership is particularly lacking in the United States, and there is a real risk that this will cost lives.

Responding to the Texas outbreak, Robert F. Kennedy Jr, the secretary of the US Department of Health and Human Services (HHS), has acknowledged that vaccines are important. But he has simultaneously, and irresponsibly, praised the benefits of cod liver oil and vitamin A supplements for treating the disease. Moreover, he has postponed a meeting of vaccine advisers to the US Centers for Disease Control and Prevention (CDC). The meeting, which was due to have been held at the end of February, was yet to be rescheduled when Nature went to press. Kennedy has also said that the HHS will investigate the recommended childhood vaccination schedule. He should outline the scientific evidence for this move and provide reassurance that there will not be a reduction in vaccines coverage.

rm

Earlier this month, the US National Institutes of Health (NIH) cut funding for crucial research aiming to understand why some people are hesitant to get themselves, or their children, vaccinated. Neither the NIH nor the HHS has issued a public communication to explain the reasons for this, nor why the CDC is reportedly planning a new study into whether vaccines cause autism.

Running such a study at a time of extreme cost-cutting makes little sense. If it goes ahead, the CDC or the HHS should publish the terms of reference and ensure that there is an open call for proposals, so all those with relevant knowledge, experience and qualifications can apply. Although Nature would generally be the first to support scientific studies, in this case it's imperative to take into account what is already known: namely, that extensive research has not found any link between vaccines and autism.

In one landmark study, for instance, researchers in Denmark recorded the vaccination status of more than 650,000 children born in the country from 1999 to 2010. They combined those data, on measles, mumps and rubella (MMR) vaccines, with data on autism spectrum disorder diagnoses. They found no difference in incidences of autism between vaccinated and unvaccinated children (A. Hviid et al. Ann. Intern. Med. 170, 513–520; 2019).

Many people have serious concerns and questions about vaccines; some are hesitant to receive vaccines and some refuse to be vaccinated. All of those involved in vaccine provision, from public-health staff to physicians and policymakers to researchers, need to listen to people's worries. Questions should be answered using the best available knowledge; what is and isn't known should be communicated transparently; and the benefits and the risks (including possible side effects) must be explained clearly.

Responsible leaders should draw on the many decades of accumulated knowledge on vaccines and encourage people to look at data that support getting vaccinated. They should not propagate ideas that are out of line with accepted, fact-based public-health advice. People who avoid vaccines are putting their own lives and those of their families and communities at unnecessary risk.

It is often said that the first responsibility of any government is the safety and protection of its people. That alone should be reason enough for policymakers to encourage people to get themselves and their children vaccinated. Vaccines save lives, and casting doubt on their safety could have dangerous and far-reaching consequences.

Nature Biotechnology

Volume 43 Issue 3, March 2025

<https://www.nature.com/nbt/volumes/43/issues/3>

[New issue; No digest content identified]

Nature Communications

<https://www.nature.com/subjects/health-sciences/ncomms>

(Accessed 22 Mar 2025)

[Reviewed earlier]

Nature Genetics

Volume 57 Issue 3, March 2025

<https://www.nature.com/ng/volumes/57/issues/3>

[Reviewed earlier]

Nature Human Behaviour

Volume 9 Issue 2, February 2025

<https://www.nature.com/nathumbehav/volumes/9/issues/2>

[Reviewed earlier]

Nature Medicine

Volume 31 Issue 2, February 2025

<https://www.nature.com/nm/volumes/31/issues/2>

[Reviewed earlier]

Nature Reviews Drug Discovery

Volume 24 Issue 3, March 2025

<https://www.nature.com/nrd/volumes/24/issues/3>

[Reviewed earlier]

Nature Reviews Genetics

Volume 26 Issue 3, March 2025

<https://www.nature.com/nrg/volumes/26/issues/3>

[Reviewed earlier]

Nature Reviews Immunology

Volume 25 Issue 3, March 2025

<https://www.nature.com/nri/volumes/25/issues/3>

[Reviewed earlier]

New England Journal of Medicine

Volume 392 No. 11 March 13/20, 2025

<https://www.nejm.org/toc/nejm/medical-journal>

[New issue; No digest content identified]

NEJM Evidence

Volume 4 No. 2 February 2025

<https://evidence.nejm.org/toc/evid/current>

NEJM Evidence, a new monthly digital journal from NEJM Group, presents innovative original research and fresh, bold ideas in clinical trial design and clinical decision-making.

[Reviewed earlier]

njp Vaccines

<https://www.nature.com/npjvaccines/>

[Accessed 22 Mar 2025]

[No new digest content identified]

Pediatrics

Volume 155, Issue 3 March 2025

<https://publications.aap.org/pediatrics/issue/155/3>

[Reviewed earlier]

PharmacoEconomics

Volume 43, Issue 3 March 2025

<https://link.springer.com/journal/40273/volumes-and-issues/43-3>

[Reviewed earlier]

PLoS Biology

<https://journals.plos.org/plosbiology/>

(Accessed 22 Mar 2025)

[Microbiota isolate collections: A key to global vector-borne disease control](#)

Miguel Medina Muñoz, Holly L. Nichols, Kerri L. Coon

Perspective | published 18 Mar 2025 PLOS Biology

<https://doi.org/10.1371/journal.pbio.3003078>

Abstract

Insect vector microbiomes are essential for insect function, making them promising targets for controlling vector-borne diseases. Microbial isolate collections aid in identifying microbial targets, but expanding these collections must rely on coordinated efforts that are ethical and ensure equitable benefit sharing.

PLoS Genetics

<https://journals.plos.org/plosgenetics/>

(Accessed 22 Mar 2025)

[No new digest content identified]

PLoS Global Public Health

https://journals.plos.org/globalpublichealth/search?sortOrder=DATE_NEWEST_FIRST&filterStartDate=2021-10-01&filterJournals=PLOSGlobalPublicHealth&q=&resultsPerPage=60

(Accessed 22 Mar 2025)

[Factors shaping Covid-19 vaccine acceptability among young people in South Africa and Nigeria: An exploratory qualitative study](#)

Marisa Casale, Oluwaseyi Somefun, Genevieve Haupt Ronnie, Joshua Sumankuuro, Olagoke Akintola, Lorraine Sherr, Lucie Cluver

Research Article | published 18 Mar 2025 PLOS Global Public Health

<https://doi.org/10.1371/journal.pgph.0003795>

Public Health

<https://doi.org/10.1371/journal.pgph.0003851>

PLoS Medicine

<https://journals.plos.org/plosmedicine/>

(Accessed 22 Mar 2025)

[No new digest content identified]

PLoS Neglected Tropical Diseases

<http://www.plosntds.org/>

(Accessed 22 Mar 2025)

[No new digest content identified]

PLoS One

<http://www.plosone.org/>

[Accessed 22 Mar 2025]

[Immunogenicity and safety of measles-mumps-rubella vaccine delivered by the aerosol, intradermal and intramuscular routes in previously vaccinated young adults: a randomized controlled trial protocol](#)

Sumanta Saha, Melanie Millier, Ari Samaranayaka, Liza Edmonds, Emma Best, James Ussher, Andrew Anglemeyer, Jennifer Lee, Michael Tatley, Felicity Cutts, Rob van Binnendijk, Peter McIntyre

Study Protocol | published 21 Mar 2025 PLOS ONE

<https://doi.org/10.1371/journal.pone.0318893>

[Governance and responses of health and surveillance systems to COVID-19 in BRICS countries: A scoping review protocol](#)

Adelyne Maria Mendes Pereira, Monique Azevedo Esperidião, Sílvia Karla Azevedo Vieira Andrade, João Felipe Marques Silva, Louise Celeste Rolim Silva, Adriano Silva, Isabela Barboza da Silva Tavares Amaral, Isabel Domingos Martinez dos Santos, Thalyta Cássia de Freitas Martins, Aline Degrave

Study Protocol | published 17 Mar 2025 PLOS ONE

<https://doi.org/10.1371/journal.pone.0319572>

PLoS Pathogens

<http://journals.plos.org/plospathogens/>

[Accessed 22 Mar 2025]

[No new digest content identified]

PNAS - Proceedings of the National Academy of Sciences of the United States

March 18, 2025 vol. 122 no. 11

<https://www.pnas.org/toc/pnas/122/12>

[New issue; No digest content identified]

PNAS Nexus

Volume 4, Issue 2, February 2025

<https://academic.oup.com/pnasnexus/issue/4/2>

[Reviewed earlier]

Prehospital & Disaster Medicine

Volume 39 - Issue 6 - December 2024

<https://www.cambridge.org/core/journals/prehospital-and-disaster-medicine/latest-issue>

[Reviewed earlier]

Preventive Medicine

Volume 191 February 2025

<https://www.sciencedirect.com/journal/preventive-medicine/vol/191/suppl/C>

[Reviewed earlier]

Proceedings of the Royal Society B

March 2025 Volume 292 Issue 2042

<https://royalsocietypublishing.org/toc/rspb/current>

[Reviewed earlier]

Public Health

Volume 240 Pages 1-222 (March 2025)

<https://www.sciencedirect.com/journal/public-health/vol/240/suppl/C>

[Reviewed earlier]

Public Health Ethics

Volume 18, Issue 1, April 2025

<http://phe.oxfordjournals.org/content/current>

[New issue; No digest content identified]

Public Health Genomics

2025, Vol. 28, No. 1

<https://karger.com/phg/issue/28/1>

[Reviewed earlier]

Public Health Reports

Volume 140 Issue 1, January/February 2025

<https://journals.sagepub.com/toc/phrg/140/1>

[Reviewed earlier]

Qualitative Health Research

Volume 35 Issue 3, March 2025

<https://journals.sagepub.com/toc/QHR/current>

[Reviewed earlier]

Research Ethics

Volume 21 Issue 1, January 2025

<http://journals.sagepub.com/toc/reab/current>

[Reviewed earlier]

Reproductive Health

<http://www.reproductive-health-journal.com/content>

[Accessed 22 Mar 2025]

[No new digest content identified]

**Revista Panamericana de Salud Pública/Pan American Journal of Public Health
(RPSP/PAJPH)**

<https://www.paho.org/journal/en>

Latest Articles

20 Mar 2025

[Lessons learned in the implementation of measles and rubella vaccination campaigns in the Americas](#)

Review | Spanish

Risk Analysis

Volume 45, Issue 2 pages: 265-472 February 2025

<https://onlinelibrary.wiley.com/toc/15396924/current>

[Reviewed earlier]

Risk Management and Healthcare Policy

<https://www.dovepress.com/risk-management-and-healthcare-policy-archive56>

[Accessed 22 Mar 2025]

[No new digest content identified]

Royal Society Open Science

March 2025 Volume 12 Issue 3

<https://royalsocietypublishing.org/toc/rsos/current>

[Reviewed earlier]

Science

Volume 387| Issue 6740| 21 Mar 2025

<https://www.science.org/toc/science/current>

Policy Forum

[Is flat 15% fair?](#)

BY Jeongwon Choi, et al.

13 Mar 2025: 1258-1259

An NIH funding policy is misguided and damaging

Science and Engineering Ethics

Volume 31, Issue 1 February 2025

<https://link.springer.com/journal/11948/volumes-and-issues/31-1>

[Reviewed earlier]

Science Translational Medicine

Volume 17| Issue 790| 19 Mar 2025

<https://www.science.org/toc/stm/current>

[New issue; No digest content identified]

Scientific Reports

<https://www.nature.com/srep/articles?type=article>

[Accessed 22 Mar 2025]

[No new digest content identified]

Social Science & Medicine

Volume 370 April 2025

<https://www.sciencedirect.com/journal/social-science-and-medicine/vol/370/suppl/C>

[Reviewed earlier]

Systematic Reviews

<https://systematicreviewsjournal.biomedcentral.com/articles>

[Accessed 22 Mar 2025]

[No new digest content identified]

Theoretical Medicine and Bioethics

Volume 46, Issue 1 February 2025

<https://link.springer.com/journal/11017/volumes-and-issues/46-1>

Special Issue on Bioethics and Language

Issue Editor: Matthew Vest

[New issue; No digest content identified]

Travel Medicine and Infectious Diseases

Volume 64 March–April 2025

<https://www.sciencedirect.com/journal/travel-medicine-and-infectious-disease/vol/64/suppl/C>

[New issue; No digest content identified]

Tropical Medicine & International Health

Volume 30, Issue 3 Pages: i-iv, 143-230 March 2025

<https://onlinelibrary.wiley.com/toc/13653156/current>

[Reviewed earlier]

Vaccine

Volume 51 2 April 2025

<https://www.sciencedirect.com/journal/vaccine/vol/51/suppl/C>

[Reviewed earlier]

Vaccines

<https://www.mdpi.com/journal/vaccines>

[Accessed 22 Mar 2025]

Open Access Review

[Innovations, Challenges, and Future Prospects for Combination Vaccines Against Human Infections](#)

by Munazza Fatima and Kee-Jong Hong

Vaccines 2025, 13(4), 335; <https://doi.org/10.3390/vaccines13040335> - 21 Mar 2025

Abstract

Combination vaccines provide the versatile benefits of addressing different pathogens simultaneously using a combined formulation. This approach can be regarded as a substantial modernization in immunization. In this review, we highlight various advancements in combination vaccines based on mRNA, viral vectors, live attenuated, [...]

Value in Health

March 2025 Volume 28 Issue 3p323-488

<https://www.valueinhealthjournal.com/current>

[Reviewed earlier]

World Development

Volume 187 March 2025

<https://www.sciencedirect.com/journal/world-development/vol/187/suppl/C>

[Reviewed earlier]

.....
.....

Contents [click to move among sections]

:: [Milestones, Perspectives](#)

:: [WHO](#)

:: [Organization Announcements](#)

:: [Journal Watch](#)

:: [Pre-Print Servers](#)

.....
.....

Pre-Print Servers

arxiv

<https://arxiv.org/>

[Accessed 22 Mar 2025]

[Filters: *Emerging Technologies; Neural and Evolutionary Computing; Computers and Society; Genomics; Neurons and Cognition; Populations and Evolution; Other Quantitative Biology; General Economics*]

[arXiv:2503.15960](https://arxiv.org/abs/2503.15960) (cross-list from math.OC) [pdf, html, other]

[Optimal Vaccination Strategies for an Heterogeneous SIS Model](#)

Jean-François Delmas (CERMICS), Dylan Dronnier, Pierre-André Zitt (LAMA)

We study in a general mathematical framework the optimal allocation of vaccine in an heterogeneous population. We cast the problem of optimal vaccination as a bi-objective minimization problem $\min(C(\eta), L(\eta))$, where C and L stand respectively for the cost and the loss incurred when following the vaccination strategy η , where the function $\eta(x)$ represents the proportion of non-vaccinated among individuals of feature [this http URL](#) measure the loss, we consider either the effective reproduction number, a classical quantity appearing in many models in epidemiology, or the overall proportion of infected individuals after vaccination in the maximal equilibrium, also called the endemic state. We only make few assumptions on the cost $C(\eta)$, which cover in particular the uniform cost, that is, the total number of vaccinated [this http URL](#) analysis of the bi-objective problem is carried in a general framework, and we check that it is well posed for the SIS model and has Pareto optima, which can be

interpreted as the ``best" vaccination strategies. We provide properties of the corresponding Pareto frontier given by the outcomes ($C(\eta)$, $L(\eta)$) of Pareto optimal strategies.

Gates Open Research

<https://gatesopenresearch.org/browse/articles>

[Accessed 22 Mar 2025]

[No new digest content identified]

medRxiv

<https://www.medrxiv.org/content/about-medrxiv>

[Accessed 22 Mar 2025]

[Filter: All articles]

[Open-source solution for evaluation and benchmarking of large language models for public health](#)

Laura Espinosa, Djilani Kebaili, Sergio Consoli, Kyriaki Kalimeri, Yelena Mejova, Marcel Salathé
medRxiv 2025.03.20.25324040; doi: <https://doi.org/10.1101/2025.03.20.25324040> Revision

[Post-pandemic changes in population immunity have reduced the likelihood of emergence of zoonotic coronaviruses](#)

Ryan M Imrie, Laura A Bissett, Savitha Raveendran, Maria Manali, Julien A R Amat, Laura Mojsiejczuk, Nicola Logan, Andrew Park, Marc Baguelin, Mafalda Viana, Brian J Willett, Pablo R Murcia
medRxiv 2025.03.17.25323820; doi: <https://doi.org/10.1101/2025.03.17.25323820>

[Post-pandemic changes in population immunity have reduced the likelihood of emergence of zoonotic coronaviruses](#)

Ryan M Imrie, Laura A Bissett, Savitha Raveendran, Maria Manali, Julien A R Amat, Laura Mojsiejczuk, Nicola Logan, Andrew Park, Marc Baguelin, Mafalda Viana, Brian J Willett, Pablo R Murcia
medRxiv 2025.03.17.25323820; doi: <https://doi.org/10.1101/2025.03.17.25323820>

OSF Pre-prints

<https://osf.io/preprints/discover?provider=OSF&subject=bepress%7CLife%20Sciences>

[Provider Filter: OSF Pre-prints Subject filters: Medicine and Health Sciences Format Filter: Pre-prints]

[Website not responding at inquiry]

Wellcome Open Research

<https://wellcomeopenresearch.org/browse/articles>

[Accessed 22 Mar 2025]

Review Open Access

[Community engagement for artificial intelligence health research in Africa](#)

[version 1; peer review: awaiting peer review]

Harriet Nankya, et al.

Abstract

Artificial Intelligence holds the potential to benefit communities in numerous areas, including health. Artificial intelligence health research is, among other things, advancing the accuracy of diagnosis, enabling new drug and treatment options, and reducing costs in healthcare. Like elsewhere, artificial intelligence health research is rapidly expanding across the African continent; however, numerous co-travelling ethical challenges - including those related to data protection, equitable access, and data colonization - are under-addressed. Community engagement is a process through which a number of

pertinent health research ethics issues affecting communities can be identified and collaboratively pursued; however, there currently is limited understanding of the opportunities and challenges for community engagement in artificial intelligence research globally. In order to advance collective understanding and support policy and practice innovation, this paper interrogates how communities in Africa could be engaged in artificial intelligence health research. It provides a justification for community engagement in artificial intelligence health research, and discusses its application in African communities. It concludes by offering some context-specific recommendations for priority attention.

*

*

*

*

Think Tanks

Brookings [to 22 Mar 2025]

<http://www.brookings.edu/>

Reports, Events

5 years after COVID-19 hit: Test data converge on math gains, stalled reading recovery

K-12 Education

Megan Kuhfeld, Karyn Lewis

March 18, 2025

Center for Global Development [to 22 Mar 2025]

<https://www.cgdev.org/>

All Research

No new digest content identified.

Chatham House [to 22 Mar 2025]

<https://www.chathamhouse.org/>

Selected Analysis, Comment, Events

No new digest content identified.

Council on Foreign Relations [to 22 Mar 2025]

<https://www.cfr.org/media/news-releases>

New Releases [Selected]

No new digest content identified.

CSIS [to 22 Mar 2025]

<https://www.csis.org/>

Reports [Selected]

No new digest content identified.

Kaiser Family Foundation [to 22 Mar 2025]

https://www.kff.org/search/?post_type=press-release

Newsroom

No new digest content identified.

McKinsey Global Institute [to 22 Mar 2025]

<https://www.mckinsey.com/mgi/overview>

Latest Research

No new digest content identified.

ODI [Overseas Development Institute] [to 22 Mar 2025]

<https://odi.org/en/publications/>

Publications [Selected]

No new digest content identified.

Pew Research Center [to 22 Mar 2025]

<https://www.pewresearch.org/>

Latest Publications [Selected]

short reads Mar 20, 2025

[More Americans report getting a flu shot than the updated COVID-19 vaccine since August](#)

Just over half of U.S. adults (53%) say they've gotten neither the flu shot nor the updated COVID-19 vaccine since last August.

Rand [to 22 Mar 2025]

<https://www.rand.org/pubs.html>

Published Research [Selected]

Expert Insights Mar 10, 2025

[Policy Options to Prevent the Creation of Mirror Organisms](#)

Ongoing research could lead to the creation of mirror organisms, whose molecular components are mirror images of those found in nature. This paper examines policy options to prevent their creation, given the potential risks such organisms pose.

Urban Institute [to 22 Mar 2025]

<https://www.urban.org/publications>

[New Research Publications - Selected](#)

World Economic Forum [to 22 Mar 2025]

<https://agenda.weforum.org/press/>

Media [Selected]

No new digest content identified.

Contents [click to move among sections]

:: [Milestones, Perspectives](#)

:: [WHO](#)

:: [Organization Announcements](#)

:: [Journal Watch](#)

:: [Pre-Print Servers](#)

| | | | |
|---|---|---|---|
| * | * | * | * |
| * | * | * | * |

Vaccines and Global Health: The Week in Review is a service of the Center for Vaccine Ethics and Policy (CVEP) / GE2P2 Global Foundation, which is solely responsible for its content.

.....

Copyright GE2P2 Global Foundation 2025. Some Rights Reserved.

This work is licensed under the Creative Commons Attribution 4.0 International License. To view a copy of this license, visit <http://creativecommons.org/licenses/by/4.0/> or send a letter to Creative Commons, PO Box 1866, Mountain View, CA 94042, USA.

Under the terms of this license, you may copy, redistribute, and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that the GE2P2 Global Foundation endorses any specific organization, products, or services. The use of the GE2P2 Global Foundation logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons license.

.....

CVEP is a program of the GE2P2 Global Foundation whose purpose and mission is to advance ethical and scientific rigor in research and evidence generation for governance, policy and practice in health, human rights action, humanitarian response, heritage stewardship, education and sustainable development. The Foundation serves governments, international agencies, INGOs, civil society organizations (CSOs), commercial entities, consortia and alliances.

Support for this service is provided by the Bill & Melinda Gates Foundation; the Bill & Melinda Gates Medical Research Institute, and industry resource members Janssen/J&J, Pfizer, Sanofi US, and Takeda, (list in formation).

Support is also provided by a growing list of individuals who use this membership service to support their roles in public health, clinical practice, government, NGOs and other international institutions, academia and research organizations, and industry.

| | | | |
|---|---|---|---|
| * | * | * | * |
| * | * | * | * |